WO1996018424A1 - Breast tissue engineering - Google Patents

Breast tissue engineering Download PDF

Info

Publication number
WO1996018424A1
WO1996018424A1 PCT/US1995/016424 US9516424W WO9618424A1 WO 1996018424 A1 WO1996018424 A1 WO 1996018424A1 US 9516424 W US9516424 W US 9516424W WO 9618424 A1 WO9618424 A1 WO 9618424A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
matrix
tissue
implanted
composition
Prior art date
Application number
PCT/US1995/016424
Other languages
French (fr)
Inventor
Joseph P. Vacanti
Anthony Atala
David J. Mooney
Robert S. Langer
Original Assignee
Children's Medical Center Corporation
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation, Massachusetts Institute Of Technology filed Critical Children's Medical Center Corporation
Priority to CA002207757A priority Critical patent/CA2207757C/en
Priority to EP95943847A priority patent/EP0797460B1/en
Priority to AT95943847T priority patent/ATE290892T1/en
Priority to JP8519297A priority patent/JPH10510736A/en
Priority to DE69534083T priority patent/DE69534083T2/en
Priority to MX9704454A priority patent/MX9704454A/en
Priority to AU45217/96A priority patent/AU717861B2/en
Publication of WO1996018424A1 publication Critical patent/WO1996018424A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/12Mammary prostheses and implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077Special surfaces of prostheses, e.g. for improving ingrowth
    • A61F2002/0086Special surfaces of prostheses, e.g. for improving ingrowth for preferentially controlling or promoting the growth of specific types of cells or tissues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0003Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having an inflatable pocket filled with fluid, e.g. liquid or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/04Materials or treatment for tissue regeneration for mammary reconstruction

Definitions

  • This invention is generally in the field of reconstruction and augmentation of breast tissue.
  • each mammary gland is modified sweat glands that are attached to the underlying muscle of the anterior chest wall by a layer of connective tissue.
  • each mammary gland consists of 15-25 lobes, separated by dense connective tissue formed primarily by fibroblasts and bundles of collagen fibers, and adipose tissue containing adipose (fat) cells held together by reticular and collagen fibers.
  • adipose tissue containing adipose (fat) cells held together by reticular and collagen fibers.
  • lactiferous duct Within each lobe is a lactiferous duct that branches extensively. At the ends of the smallest branches are the glandular epithelial cells (alveolar cells) that synthesize and secrete milk into the duct system.
  • the ducts which are composed of simple cuboidal and columnar epithelium, and the alveolar cells are embedded in loose connective tissue containing collagen fibers and fibroblasts, lymphocytes, and plasma cells that secrete immunoglobulin A into the milk, conferring passive immunity on the newborn.
  • epithelial cells Just external to the alveolar and duct epithelial cells are myoepithelial cells that respond to neural and hormonal stimuli by contracting and expressing the milk.
  • Each lactiferous duct opens onto the surface of the breast through the skin covering the nipple.
  • Cosmetic surgeries include augmentation, for example, using implants; reduction; and reconstruction.
  • Therapeutic surgery which is the primary treatment for most early cancers, includes radical surgery that may involve removal of the entire soft tissue anterior chest wall and lymph nodes and vessels extending into the head and neck; lumpectomy, which may involve only a small portion of the breast; and laser surgery for destruction of small regions of tissue. Reconstructive surgery and the use of implants is frequently combined with radical breast surgery.
  • the radical mastectomy involves removal of the breast, both the major and minor pectoralis muscles, and lymph nodes.
  • Reconstructive procedures frequently involve moving vascularized skin flaps with underlying connective and adipose tissue from one region of the body, e.g., the buttocks or the abdominal region, to the breast region. Surgeons also use breast implants for reconstruction.
  • silicone prosthesis which are used for reconstruction and augmentation, have caused numerous medical complications. It would be desirable to have an alternative material for implantation. Even with reconstructive surgical methods that are currently in use, it is extremely difficult to achieve tissue that looks and feels normal, particularly when there has been extensive removal of associated muscle tissue.
  • Dissociated cells preferably muscle cells
  • a suitable biodegradable, polymeric matrix to form new tissue.
  • matrices which can be used: a polymeric hydrogel formed of a material such as alginate having cells suspended therein, and a fibrous matrix having an interstitial spacing between about 100 and 300 microns.
  • Preferred polymeric materials are those degrading over about one to two months, such as polylactic acid-glycolic acid copolymers.
  • the matrices can be seeded prior to implantation or implanted, allowed to vascularize, then seeded with cells.
  • the cell-matrix structures are implanted in combination with tissue expander devices. As cell-matrix is implanted, or cells proliferate and form new tissue, the expander size is decreased, until it can be removed and the desired reconstruction or augmentation is obtained.
  • the preferred cell types are muscle cells, although other types of mesenchymal cells, fibroblasts, chondrocytes, and adipocytes can be used. Cells obtained from tissue such as the labia can be used for specialized applications such as formation of a nipple type tissue. Other materials, such as bioactive molecules that enhance vascularization of the implanted tissue and/or which inhibit ingrowth of fibrotic tissue, can be implanted with the matrix to enhance development of more normal tissue.
  • the cell-matrix structures can be implanted at the time of surgery to remove cancerous breast tissue, during subsequent reconstructive surgery, or over a period of time, for example, weekly, if serial injections of cell- hydrogel suspensions are used to create the new tissue.
  • Figure 1 is a schematic of the process for implantation of dissociated cells on a polymeric matrix into breast for breast tissue augmentation.
  • Figure 2 is a schematic of a fibrous plate implanted into breast tissue with struts to provide support of surrounding tissue and skin and allow new tissue to be formed within the strut following injection of a cell-hydrogel suspension.
  • Figures 3A, 3B and 3C are schematics of the serial injection of a cell-hydrogel suspension following implantation of a tissue expander, with the tissue expander being decreased in size each time the suspension is injected.
  • Figure 3A is the tissue expander maximally expanded
  • Figure 3B is with fluid withdrawn from the expander to create a space between the abutting tissue and the expander, into which cell-polymer suspension is injected
  • Figure 3C is with the expander maximally deflated, with new tissue forming in the space occupied by much of the tissue expander expanded as in Figure 1.
  • Cells to be implanted are dissociated using standard techniques such as digestion with a collagenase, trypsin or other protease solution.
  • Preferred cell types are mesenchymal cells, especially smooth or skeletal muscle cells, myocytes (muscle stem cells) , chondrocytes, adipocytes, fibromyoblasts, and ectodermal cells, including ductile and skin cells. In some cases it may also be desirable to include nerve cells.
  • Cells can be normal or genetically engineered to provide additional or normal function.
  • Cells are preferably autologous cells, obtained by biopsy and expanded in culture, although cells from close relatives or other donors of the same species may be used with appropriate immunosuppression.
  • Immunologically inert cells such as embryonic cells, stem cells, and cells genetically engineered to avoid the need for immunosuppression can also be used. Methods and drugs for immunosuppression are known to those skilled in the art of transplantation.
  • a preferred compound is cyclosporin using the recommended dosages.
  • skeletal or smooth muscle cells are obtained by biopsy and expanded in culture for subsequent implantation.
  • Skeletal or smooth can be easily obtained through a biopsy anywhere in the body, for example, skeletal muscle biopsies can be obtained easily from the arm, forearm, or lower extremities, and smooth muscle can be obtained from the area adjacent to the subcutaneous tissue throughout the body. To obtain either type of muscle, the area to be biopsied can be locally anesthetized with a small amount of lidocaine injected subcutaneously.
  • a small patch of lidocaine jelly can be applied over the area to be biopsied and left in place for a period of 5 to 20 minutes, prior to obtaining biopsy specimen.
  • the biopsy can be effortlessly obtained with the use of a biopsy needle, a rapid action needle which makes the procedure extremely simple and almost painless. With the addition of the anesthetic agent, the procedure would be entirely painless.
  • This small biopsy core of either skeletal or smooth muscle can then be transferred to media consisting of phosphate buffered saline.
  • the biopsy specimen is then transferred to the lab where the muscle can be grown utilizing the explant technique, wherein the muscle is divided into very pieces which are adhered to culture plate, and serum containing media is added.
  • the muscle biopsy can be enzymatically digested with agents such as trypsin and the cells dispersed in a culture plate with any of the routinely used medias. After cell expansion within the culture plate, the cells can be easily passaged utilizing the usual technique until an adequate number of cells is achieved.
  • Bioerodible or “biodegradable”, as used herein refers to materials which are enzymatically or chemically degraded in vivo into simpler chemical species. Hvdro ⁇ el Polymer Solutions
  • polymers that can form ionic hydrogels which are malleable are used to support the cells.
  • Injecting a suspension of cells in a polymer solution may be performed to improve the reproducibility of cell seeding throughout a device, to protect the cells from shear forces or pressure induced necrosis, or to aid in defining the spatial location of cell delivery.
  • the injectable polymer may also be utilized to deliver cells and promote the formation of new tissue without the use of any other matrix.
  • the hydrogel is produced by cross-linking the ionic salt of a polymer with ions, whose strength increases with either increasing concentrations of ions or polymer.
  • the polymer solution is mixed with the cells to be implanted to form a suspension, which is then injected directly into a patient prior to hardening of the suspension.
  • the suspension subsequently hardens over a short period of time due to the presence in vivo of physiological concentrations of ions such as calcium in the case where the polymer is a polysaccharide such as alginate.
  • a hydrogel is defined as a substance formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel.
  • Examples of materials which can be used to form a hydrogel include polysaccharides such as alginate, polyphosphazenes, and polyacrylates such as hydroxyethyl methacrylate (HEMA) , which are crosslinked ionically, or block copolymers such as PluronicsTM or TetronicsTM, polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or pH, respectively.
  • HEMA hydroxyethyl methacrylate
  • PluronicsTM or TetronicsTM polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or pH, respectively.
  • Other materials include proteins such as fibrin, polymers such as polyvinylpyrrolidone, hyaluronic acid and collagen.
  • these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof.
  • aqueous solutions such as water, buffered salt solutions, or aqueous alcohol solutions
  • polymers with acidic side groups that can be reacted with cations are poly(phosphazenes) , poly(acrylic acids) , poly(methacrylic acids) , copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene.
  • Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used.
  • acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH
  • the ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups.
  • basic side groups are amino and imino groups.
  • Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Due to these mild conditions, alginate has been the most commonly used polymer for hybridoma cell encapsulation, as described, for example, in U.S. Patent No.
  • an aqueous solution containing the biological materials to be encapsulated is suspended in a solution of a water soluble polymer, the suspension is formed into droplets which are configured into discrete microcapsules by contact with multivalent cations, then the surface of the microcapsules is crosslinked with polyamino acids to form a semipermeable membrane around the encapsulated materials.
  • Polyphosphazenes are polymers with backbones consisting of nitrogen and phosphorous separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two side chains (“R") .
  • R side chains
  • the repeat unit in polyphosphazenes has the general structure: R
  • n is an integer.
  • the polyphosphazenes suitable for cross- linking have a majority of side chain groups which are acidic and capable of forming salt bridges with di- or trivalent cations.
  • preferred acidic side groups are carboxylic acid groups and sulfonic acid groups.
  • Hydrolytically stable polyphosphazenes are formed of monomers having carboxylic acid side groups that are crosslinked by divalent or trivalent cations such as Ca 2t or Al 3* . Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side groups.
  • a polyanionic poly [bis (carboxylatophenoxy) ] phosphazene (PCPP) can be synthesized, which is cross-linked with dissolved multivalent cations in aqueous media at room temperature or below to form hydrogel matrices.
  • Bioerodible polyphosphazenes have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze under in vivo conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl .
  • bioerodible or biodegrable means a polymer that dissolves or degrades within a period that is acceptable in the desired application (usually in vivo therapy) , less than about five years and most preferably less than about one year, once exposed to a physiological solution of pH 6-8 having a temperature of between about 25°C and 38°C. Hydrolysis of the side chain results in erosion of the polymer. Examples of hydrolyzing side chains are unsubstituted and substituted imidizoles and amino acid esters in which the group is bonded to the phosphorous atom through an amino linkage (polyphosphazene polymers in which both R groups are attached in this manner are known as polyaminophosphazenes) .
  • R groups on the polyphosphazene backbone are imidazole rings, attached to phosphorous in the backbone through a ring nitrogen atom.
  • Other "R” groups can be organic residues that do not participate in hydrolysis, such as methyl phenoxy groups or other groups shown in the scientific paper of Allcock, et al., Macromolecule 10:824-830 (1977) .
  • the preferred cations for cross-linking of the polymers with acidic side groups to form a hydrogel are divalent and trivalent cations such as copper, calcium, aluminum, magnesium, strontium, barium, and tin, although di-, tri- or tetra- functional organic cations such as alkylammonium salts, e.g., R 3 N* - ⁇ / ⁇ / ⁇ /- + NR 3 can also be used.
  • Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes. The higher the concentration of cation, or the higher the valence, the greater the degree of cross-linking of the polymer. Concentrations from as low as 0.005 M have been demonstrated to cross-link the polymer. Higher concentrations are limited by the solubility of the salt.
  • the preferred anions for cross-linking of the polymers to form a hydrogel are divalent and trivalent anions such as low molecular weight dicarboxylic acids, for example, terepthalic acid, sulfate ions and carbonate ions.
  • Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.
  • polycations can be used to complex and thereby stabilize the polymer hydrogel into a semi-permeable surface membrane.
  • materials that can be used include polymers having basic reactive groups such as amine or imine groups, having a preferred molecular weight between 3,000 and 100,000, such as polyethylenimine and polylysine. These are commercially available.
  • One polycation is poly(L-lysine)
  • examples of synthetic polyamines are: polyethyleneimine, poly(vinylamine) , and poly(allyl amine) .
  • There are also natural polycations such as the polysaccharide, chitosan.
  • Polyanions that can be used to form a semi-permeable membrane by reaction with basic surface groups on the polymer hydrogel include polymers and copolymers of acrylic acid, methacrylic acid, and other derivatives of acrylic acid, polymers with pendant S0 3 H groups such as sulfonated polystyrene, and polystyrene with carboxylic acid groups.
  • the polymer is dissolved in an aqueous solution, preferably a 0.1 M potassium phosphate solution, at physiological pH, to a concentration forming a polymeric hydrogel, for example, for alginate, of between 0.5 to 2% by weight, preferably 1%, alginate.
  • a concentration forming a polymeric hydrogel for example, for alginate, of between 0.5 to 2% by weight, preferably 1%, alginate.
  • the isolated cells are suspended in the polymer solution to a concentration of between 1 and 50 million cells/ml, most preferably between 10 and 20 million cells/ml.
  • the matrices For an organ to be constructed, successfully implanted, and function, the matrices must have sufficient surface area and exposure to nutrients such that cellular growth and differentiation can occur prior to the ingrowth of blood vessels following implantation. The time required for successful implantation and growth of the cells within the matrix is greatly reduced if the area into which the matrix is implanted is prevascularized. After implantation, the configuration must allow for diffusion of nutrients and waste products and for continued blood vessel ingrowth as cell proliferation occurs.
  • the organization of the tissue may be regulated by the microstructure of the matrix. Specific pore sizes and structures may be utilized to control the pattern and extent of fibrovascular tissue ingrowth from the host, as well as the organization of the implanted cells.
  • the surface geometry and chemistry of the matrix may be regulated to control the adhesion, organization, and function of implanted cells or host cells.
  • the matrix is formed of polymers having a fibrous structure which has sufficient interstitial spacing to allow for free diffusion of nutrients and gases to cells attached to the matrix surface. This spacing is typically in the range of 100 to 300 microns, although closer spacings can be used if the matrix is implanted, blood vessels allowed to infiltrate the matrix, then the cells are seeded into the matrix.
  • "fibrous” includes one or more fibers that is entwined with itself, multiple fibers in a woven or non-woven mesh, and sponge like devices.
  • Cells can either be implanted after seeding onto a matrix or injected into a matrix already implanted at the desired site.
  • the latter has the advantage that the matrix can be used to prevascularize the site.
  • the matrix should be a pliable, non- toxic, injectable porous template for vascular ingrowth.
  • the pores should allow vascular ingrowth and the injection of cells such as muscle cells without damage to the cells or patient. These are generally interconnected pores in the range of between approximately 100 and 300 microns.
  • the matrix should be shaped to maximize surface area, to allow adequate diffusion of nutrients and growth factors to the cells and to allow the ingrowth of new blood vessels and connective tissue.
  • a porous structure that is resistant to compression is preferred for implantation, prevascularization, followed by seeding.
  • the matrix is prevascularized, it may be desirable to incorporate into the matrix means for dispersing the cells throughout the matrix, for example, using catheters which can be removed following seeding.
  • the overall, or external, matrix configuration is dependent on the tissue which is to reconstructed or augmented.
  • the cell-matrix structure will be similar to the silicone implants now used, which are essentially disks that deform due to gravity to form a teardrop shape.
  • the shape can also be obtained using struts, as described below, to impart resistance to mechanical forces and thereby yield the desired shape.
  • the shape of the matrix per se will not be disk shaped, but will appear disk shaped when seeded with the cells to be implanted, or will create the outline of a disk or tear drop shape following implantation.
  • Polymers Either natural or synthetic polymers can be used to form the matrix, although synthetic polymers are preferred for reproducibility and controlled release kinetics.
  • Synthetic polymers that can be used include bioerodible polymers such as poly(lactide) (PLA) , poly(glycolic acid) (PGA) , poly(lactide-co-glycolide) (PLGA) , poly(caprolactone) , polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole) , chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, teflon ® , and nylon.
  • bioerodible polymers such as poly(lactide
  • non-degradable materials can be used to form the matrix or a portion of the matrix, they are not preferred.
  • the preferred non-degradable material for implantation of a matrix which is prevascularized prior to implantation of dissociated cells is a polyvinyl alcohol sponge, or alkylation, and acylation derivatives thereof, including esters.
  • a non- absorbable polyvinyl alcohol sponge is available commercially as IvalonTM, from Unipoint Industries. Methods for making this material are described in U.S. Patent Nos. 2,609,347 to Wilson; 2,653,917 to Hammon, 2,659,935 to Hammon, 2,664,366 to Wilson, 2,664,367 to Wilson, and 2,846,407 to Wilson, the teachings of which are incorporated by reference herein. These materials are all commercially available.
  • natural polymers include proteins such as albumin, collagen, synthetic polyamino acids, and prolamines, and polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units.
  • PLA, PGA and PLA/PGA copolymers are particularly useful for forming the biodegradable matrices.
  • PLA polymers are usually prepared from the cyclic esters of lactic acids. Both L(+) and D(-) forms of lactic acid can be used to prepare the PLA polymers, as well as the optically inactive DL-lactic acid mixture of D(-) and L(+) lactic acids. Methods of preparing polylactides are well documented in the patent literature. The following
  • PGA is the homopolymer of glycolic acid (hydroxyacetic acid) .
  • glycolic acid hydroxyacetic acid
  • glycolic acid is initially reacted with itself to form the cyclic ester glycolide, which in the presence of heat and a catalyst is converted to a high molecular weight linear-chain polymer.
  • PGA polymers and their properties are described in more detail in Cyanamid
  • the erosion of the matrix is related to the molecular weights of PLA, PGA or PLA/PGA.
  • a preferred material is poly(lactide-co-glycolide) (50:50), which degrades in about six weeks following implantation (between one and two months) . All polymers for use in the matrix must meet the mechanical and biochemical parameters necessary to provide adequate support for the cells with subsequent growth and proliferation.
  • the polymers can be characterized with respect to mechanical properties such as tensile strength using an Instron tester, for polymer molecular weight by gel permeation chromatography (GPC) , glass transition temperature by differential scanning calorimetry (DSC) and bond structure by infrared (IR) spectroscopy, with respect to toxicology by initial screening tests involving Ames assays and in vi tro teratogenicity assays, and implantation studies in animals for immunogenicity, inflammation, release and degradation studies.
  • GPC gel permeation chromatography
  • DSC differential scanning calorimetry
  • IR infrared
  • attachment of the cells to the polymer is enhanced by coating the polymers with compounds such as basement membrane components, agar, agarose, gelatin, gum arabic, collagens types I, II, III, IV, and V, fibronectin, laminin, glycosaminoglycans, polyvinyl alcohol, mixtures thereof, and other hydrophilic and peptide attachment materials known to those skilled in the art of cell culture.
  • a preferred material for coating the polymeric matrix is polyvinyl alcohol or collagen. Struts
  • struts can be biodegradable or non- degradable polymers which are inserted to form a more defined shape than is obtained using the cell- matrices, especially the hydrogel-cell suspensions.
  • An analogy can be made to a corset, with the struts acting as "stays” to push the surrounding tissue and skin up and away from the implanted cells.
  • the struts are implanted prior to or at the time of implantation of the cell-matrix structure.
  • the struts are formed of a polymeric material of the same type as can be used to form the matrix, as listed above, having sufficient strength to resist the necessary mechanical forces.
  • tissue expanders can be used to create additional space for implantation of cell-matrix structures.
  • Tissue expanders are commercially available and routinely used for expansion of skin, for example, prior to plastic surgery, as reviewed by Cohen, J. Dermatol . Sur ⁇ . Oncol. 19:614-615 (1993) , Bennett and Hirt, J. Dermatol. Surer. Oncol. 19:1066-1073 (1993) , Hammond, et al. , Plastic and Reconstructive Surgery, 92 (2) :255-259 (1993) , Walton and Brown, Annals of Plastic Surgery 30(2), 105-110 (February 1993), Kenna, et al.
  • tissue expander When skin is tensioned for long periods of time, weeks to months, it responds by a very significant stretching. This is associated with metabolic activity and tissue growth.
  • the generally accepted definition of a tissue expander is a device that resides beneath the surface of the skin which is used to stretch the skin.
  • a spherical tissue expander is a multi ⁇ dimensional expander, typically applied by volumetrically expanding a subcutaneous space with an inflatable device.
  • multiple bolus materials can be implanted and the device shrunk or replaced through removal of one or more of the bolus materials.
  • tissue expanders in breast reconstruction are well understood (see, for example, Hammond, et al., 1993) .
  • Several different types of anatomically oriented or shaped expanders have been designed to give a more natural contour to the reconstructed breast .
  • Devices are commercially available, for example, from McGhan Medical Corporation, Santa Barbara, CA, Dow Coming-Wright, Arlington, TN, and Mentor Corporation, Goleta, GA.
  • a hydrogel-cell suspension is injected into the area where tissue is to be created.
  • the space for injection of the cell- polymer suspension is created by implantation of a tissue expander prior to injection of the hydrogel- cell suspension.
  • the tissue expander is inflated or expanded through implantation of a desired number of modules, to maximize the space and skin required for formation of tissue.
  • each time cell- matrix is injected the tissue expander is deflated or a module is removed to leave a space of an equivalent amount to the volume of cell-matrix injected. Once the space is essentially filled with new tissue or cell-matrix suspension, ' the tissue expander is removed, using in most cases a local anesthetic and minor incision.
  • bioactive molecules may be delivered using the matrices described herein. These are referred to generically herein as “factors” or “bioactive factors” .
  • the bioactive factors are growth factors, angiogenic factors, compounds selectively inhibiting ingrowth of fibroblast tissue such as antiinflammatories, and compounds selectively inhibiting growth and proliferation of transformed (cancerous) cells. These factors may be utilized to control the growth and function of implanted cells, the ingrowth of blood vessels into the forming tissue, and/or the deposition and organization of fibrous tissue around the implant.
  • growth factors include heparin binding growth factor (hbgf) , transforming growth factor alpha or beta (TGF/S) , alpha fibroblastic growth factor (FGF) , epidermal growth factor (TGF) , vascular endothelium growth factor (VEGF) , some of which are also angiogenic factors.
  • Other factors include hormones such as insulin, glucagon, and estrogen. In some embodiments it may be desirable to incorporate factors such as nerve growth factor (NGF) or muscle morphogenic factor (MMP) .
  • NGF nerve growth factor
  • MMP muscle morphogenic factor
  • Steroidal antiinflammatories can be used to decrease inflammation to the implanted matrix, thereby decreasing the amount of fibroblast tissue growing into the matrix.
  • selective chemotherapeutic agents which do not inhibit growth of normal cells, such as antibody targeted chemotherapeutic agents, these can be incorporated into the matrix and used to inhibit any residual cancer cells remaining following a mastectomy.
  • the bioactive factors are incorporated to between one and 30% by weight, although the factors can be incorporated to a weight percentage between 0.01 and 95 weight percentage.
  • Bioactive molecules can be incorporated into the matrix and released over time by diffusion and/or degradation of the matrix, they can be suspended with the cell suspension, they can be incorporated into microspheres which are suspended with the cells or attached to or incorporated within the matrix, or some combination thereof.
  • Microspheres would typically be formed of materials similar to those forming the matrix, selected for their release properties rather than structural properties. Release properties can also be determined by the size and physical characteristics of the microspheres. Suitable microspheres and methods for their use in tissue generation is described in U.S. Serial No. 08/358,235 by David J. Mooney, Robert S. Langer, and Joseph P. Vacanti, entitled "Localized Delivery of Factors Enhancing Survival of Transplanted Cells", co-filed herewith in the U.S. Patent and Trademark Office on December 16, 1994, the teachings of which are incorporated herein.
  • the cell which can be a hydrogel solution or a solid fibrous matrix
  • the form of the engineered tissue can be regulated by utilizing a tissue expander to create the desired space for tissue formation, and then serially deflating the tissue expander while the cells of interest are delivered to this newly created space. This allows the tissue form to be pre-defined, and allows serial introduction of cells for form new tissue.
  • a pre-formed matrix can be implanted, allowed to vascularize, then be seeded with dissociated cells which form new tissue, preferably as the matrix degrades. Selection of the appropriate system depends on the degree of augmentation required, and determines whether the whole injection can be performed at once, or alternatively, performed in a sequential manner, so as to allow for tissue formation with adequate vascularization before subsequent injections are performed.
  • Selection of cell type can be used to vary the texture of the implanted material, as well as the appearance.
  • cartilage can be used, if a more rigid implant is desired.
  • it may be desirable to create softer tissue for example, using adipocytes or other soft tissue components.
  • Figure 1 is a schematic of the process for implantation of dissociated cells 10 on a polymeric matrix 12 into breast 14 for breast tissue augmentation.
  • the cells attach to the matrix 12, which is originally disk shaped but deforms to a tear drop shape when implanted. As vascularization occurs and the matrix degrades, new tissue is formed.
  • Figure 2 is a schematic of a fibrous plate 20 implanted into breast tissue 22 with struts 24 to provide support of surrounding tissue and skin and allow new tissue to be formed within the strut following injection of a cell-hydrogel suspension (not shown) .
  • Figures 3A, 3B and 3C are schematics of the serial injection of a cell-hydrogel suspension following implantation of a tissue expander (Figure 3A) , with the tissue expander being decreased in size each time the suspension is injected ( Figure 3B) , so that new tissue forms in the space left as the expander is decreased in volume ( Figure 3C) .

Abstract

Methods and compositions are described herein for reconstruction or augmentation of breast tissue. Dissociated cells, preferably muscle cells, are implanted in combination with a suitable biodegradable, polymeric matrix to form new tissue. There are two forms of matrices which can be used: a polymeric hydrogel formed of a material such as alginate having cells suspended therein, and a fibrous matrix having an interstitial spacing between about 100 and 300 microns. Preferred polymeric materials are those degrading over about one to two months, such as polylactic acid-glycolic acid copolymers. The matrices can be seeded prior to implantation or implanted, allowed to vascularize, then seeded with cells. In a preferred embodiment, the cell-matrix structures are implanted in combination with tissue expander devices. As cell-matrix is implanted, or cells proliferate and form new tissue, the expander size is decreased, until it can be removed and the desired reconstruction or augmentation is obtained. The preferred cell types are muscle cells, although other types of mesenchymal cells, fibroblasts, chondrocytes, and adipocytes can be used. Cells obtained from tissue such as the labia can be used for specialized applications such as formation of a nipple type tissue. Other materials, such as bioactive molecules that enhance vascularization of the implanted tissue and/or which inhibit ingrowth of fibrotic tissue, can be implanted with the matrix to enhance development of more normal tissue.

Description

BREAST TISSUE ENGINEERING
Background of the Invention
This invention is generally in the field of reconstruction and augmentation of breast tissue.
The breasts, or mammary glands, are modified sweat glands that are attached to the underlying muscle of the anterior chest wall by a layer of connective tissue. Internally, each mammary gland consists of 15-25 lobes, separated by dense connective tissue formed primarily by fibroblasts and bundles of collagen fibers, and adipose tissue containing adipose (fat) cells held together by reticular and collagen fibers. Within each lobe is a lactiferous duct that branches extensively. At the ends of the smallest branches are the glandular epithelial cells (alveolar cells) that synthesize and secrete milk into the duct system. The ducts, which are composed of simple cuboidal and columnar epithelium, and the alveolar cells are embedded in loose connective tissue containing collagen fibers and fibroblasts, lymphocytes, and plasma cells that secrete immunoglobulin A into the milk, conferring passive immunity on the newborn. Just external to the alveolar and duct epithelial cells are myoepithelial cells that respond to neural and hormonal stimuli by contracting and expressing the milk. Each lactiferous duct opens onto the surface of the breast through the skin covering the nipple.
Surgery of the breast can be broadly categorized as cosmetic and therapeutic. Cosmetic surgeries include augmentation, for example, using implants; reduction; and reconstruction. Therapeutic surgery, which is the primary treatment for most early cancers, includes radical surgery that may involve removal of the entire soft tissue anterior chest wall and lymph nodes and vessels extending into the head and neck; lumpectomy, which may involve only a small portion of the breast; and laser surgery for destruction of small regions of tissue. Reconstructive surgery and the use of implants is frequently combined with radical breast surgery. The radical mastectomy involves removal of the breast, both the major and minor pectoralis muscles, and lymph nodes.
More than 250,000 reconstructive procedures are performed on the breast each year. Women afflicted with breast cancer, congenital defects or damage resulting from trauma have very few alternatives to reconstruction. Breast reconstruction is frequently used at the time or, or shortly after, mastectomy for cancer.
Reconstructive procedures frequently involve moving vascularized skin flaps with underlying connective and adipose tissue from one region of the body, e.g., the buttocks or the abdominal region, to the breast region. Surgeons also use breast implants for reconstruction.
There are numerous surgical methods of breast reconstruction, including tissue expansion followed by silicone implantation, latissimus dorsi flap, pedicled transversus abdominis myocutaneous flap (TRAM) , free TRAM flap, and free gluteal flap. Full reconstruction often requires numerous procedures in addition to the mastectomy and primary reconstruction. Procedures include tissue- expander exchange for permanent implant, nipple reconstruction, revision of reconstruction, and mastopexy/reduction.
Unfortunately, silicone prosthesis, which are used for reconstruction and augmentation, have caused numerous medical complications. It would be desirable to have an alternative material for implantation. Even with reconstructive surgical methods that are currently in use, it is extremely difficult to achieve tissue that looks and feels normal, particularly when there has been extensive removal of associated muscle tissue.
It is therefore an object of the present invention to provide methods and compositions for reconstruction and augmentation of breast tissue.
It is a further object of the present invention to provide methods and materials to provide breast structure which is tissue, not foreign material such as silicone, and has the appearance of normal tissue.
Summary of the Invention Methods and compositions are described herein for reconstruction or augmentation of breast tissue. Dissociated cells, preferably muscle cells, are implanted in combination with a suitable biodegradable, polymeric matrix to form new tissue. There are two forms of matrices which can be used: a polymeric hydrogel formed of a material such as alginate having cells suspended therein, and a fibrous matrix having an interstitial spacing between about 100 and 300 microns. Preferred polymeric materials are those degrading over about one to two months, such as polylactic acid-glycolic acid copolymers. The matrices can be seeded prior to implantation or implanted, allowed to vascularize, then seeded with cells. In a preferred embodiment, the cell-matrix structures are implanted in combination with tissue expander devices. As cell-matrix is implanted, or cells proliferate and form new tissue, the expander size is decreased, until it can be removed and the desired reconstruction or augmentation is obtained. The preferred cell types are muscle cells, although other types of mesenchymal cells, fibroblasts, chondrocytes, and adipocytes can be used. Cells obtained from tissue such as the labia can be used for specialized applications such as formation of a nipple type tissue. Other materials, such as bioactive molecules that enhance vascularization of the implanted tissue and/or which inhibit ingrowth of fibrotic tissue, can be implanted with the matrix to enhance development of more normal tissue.
The cell-matrix structures can be implanted at the time of surgery to remove cancerous breast tissue, during subsequent reconstructive surgery, or over a period of time, for example, weekly, if serial injections of cell- hydrogel suspensions are used to create the new tissue.
Brief Description of the Drawings
Figure 1 is a schematic of the process for implantation of dissociated cells on a polymeric matrix into breast for breast tissue augmentation.
Figure 2 is a schematic of a fibrous plate implanted into breast tissue with struts to provide support of surrounding tissue and skin and allow new tissue to be formed within the strut following injection of a cell-hydrogel suspension.
Figures 3A, 3B and 3C are schematics of the serial injection of a cell-hydrogel suspension following implantation of a tissue expander, with the tissue expander being decreased in size each time the suspension is injected. Figure 3A is the tissue expander maximally expanded; Figure 3B is with fluid withdrawn from the expander to create a space between the abutting tissue and the expander, into which cell-polymer suspension is injected; and Figure 3C is with the expander maximally deflated, with new tissue forming in the space occupied by much of the tissue expander expanded as in Figure 1.
Detailed Description of the Invention
I. Cells to Be Implanted
Cells to be implanted are dissociated using standard techniques such as digestion with a collagenase, trypsin or other protease solution. Preferred cell types are mesenchymal cells, especially smooth or skeletal muscle cells, myocytes (muscle stem cells) , chondrocytes, adipocytes, fibromyoblasts, and ectodermal cells, including ductile and skin cells. In some cases it may also be desirable to include nerve cells.
Cells can be normal or genetically engineered to provide additional or normal function.
Cells are preferably autologous cells, obtained by biopsy and expanded in culture, although cells from close relatives or other donors of the same species may be used with appropriate immunosuppression. Immunologically inert cells, such as embryonic cells, stem cells, and cells genetically engineered to avoid the need for immunosuppression can also be used. Methods and drugs for immunosuppression are known to those skilled in the art of transplantation. A preferred compound is cyclosporin using the recommended dosages. In the preferred embodiment, skeletal or smooth muscle cells are obtained by biopsy and expanded in culture for subsequent implantation. Skeletal or smooth can be easily obtained through a biopsy anywhere in the body, for example, skeletal muscle biopsies can be obtained easily from the arm, forearm, or lower extremities, and smooth muscle can be obtained from the area adjacent to the subcutaneous tissue throughout the body. To obtain either type of muscle, the area to be biopsied can be locally anesthetized with a small amount of lidocaine injected subcutaneously.
Alternatively, a small patch of lidocaine jelly can be applied over the area to be biopsied and left in place for a period of 5 to 20 minutes, prior to obtaining biopsy specimen. The biopsy can be effortlessly obtained with the use of a biopsy needle, a rapid action needle which makes the procedure extremely simple and almost painless. With the addition of the anesthetic agent, the procedure would be entirely painless. This small biopsy core of either skeletal or smooth muscle can then be transferred to media consisting of phosphate buffered saline. The biopsy specimen is then transferred to the lab where the muscle can be grown utilizing the explant technique, wherein the muscle is divided into very pieces which are adhered to culture plate, and serum containing media is added. Alternatively, the muscle biopsy can be enzymatically digested with agents such as trypsin and the cells dispersed in a culture plate with any of the routinely used medias. After cell expansion within the culture plate, the cells can be easily passaged utilizing the usual technique until an adequate number of cells is achieved.
II. Device Fabrication: Three principle types of matrices can be used to create new tissues or augment tissues. The term "bioerodible" , or "biodegradable", as used herein refers to materials which are enzymatically or chemically degraded in vivo into simpler chemical species. Hvdroσel Polymer Solutions
In one embodiment, polymers that can form ionic hydrogels which are malleable are used to support the cells. Injecting a suspension of cells in a polymer solution may be performed to improve the reproducibility of cell seeding throughout a device, to protect the cells from shear forces or pressure induced necrosis, or to aid in defining the spatial location of cell delivery. The injectable polymer may also be utilized to deliver cells and promote the formation of new tissue without the use of any other matrix.
In a preferred embodiment, the hydrogel is produced by cross-linking the ionic salt of a polymer with ions, whose strength increases with either increasing concentrations of ions or polymer. The polymer solution is mixed with the cells to be implanted to form a suspension, which is then injected directly into a patient prior to hardening of the suspension. The suspension subsequently hardens over a short period of time due to the presence in vivo of physiological concentrations of ions such as calcium in the case where the polymer is a polysaccharide such as alginate.
Polymers The polymeric material which is mixed with cells for implantation into the body should form a hydrogel . A hydrogel is defined as a substance formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel. Examples of materials which can be used to form a hydrogel include polysaccharides such as alginate, polyphosphazenes, and polyacrylates such as hydroxyethyl methacrylate (HEMA) , which are crosslinked ionically, or block copolymers such as Pluronics™ or Tetronics™, polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or pH, respectively. Other materials include proteins such as fibrin, polymers such as polyvinylpyrrolidone, hyaluronic acid and collagen.
In general, these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof. Examples of polymers with acidic side groups that can be reacted with cations are poly(phosphazenes) , poly(acrylic acids) , poly(methacrylic acids) , copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene. Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used. Examples of acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH groups.
Examples of polymers with basic side groups that can be reacted with anions are poly(vinyl amines) , poly(vinyl pyridine) , poly(vinyl imidazole) , and some imino substituted polyphosphazenes. The ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups. Examples of basic side groups are amino and imino groups. Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Due to these mild conditions, alginate has been the most commonly used polymer for hybridoma cell encapsulation, as described, for example, in U.S. Patent No. 4,352,883 to Lim. In the Lim process, an aqueous solution containing the biological materials to be encapsulated is suspended in a solution of a water soluble polymer, the suspension is formed into droplets which are configured into discrete microcapsules by contact with multivalent cations, then the surface of the microcapsules is crosslinked with polyamino acids to form a semipermeable membrane around the encapsulated materials.
Polyphosphazenes are polymers with backbones consisting of nitrogen and phosphorous separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two side chains ("R") . The repeat unit in polyphosphazenes has the general structure: R
Figure imgf000011_0001
where n is an integer.
The polyphosphazenes suitable for cross- linking have a majority of side chain groups which are acidic and capable of forming salt bridges with di- or trivalent cations. Examples of preferred acidic side groups are carboxylic acid groups and sulfonic acid groups. Hydrolytically stable polyphosphazenes are formed of monomers having carboxylic acid side groups that are crosslinked by divalent or trivalent cations such as Ca2t or Al3*. Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side groups. For example, a polyanionic poly [bis (carboxylatophenoxy) ] phosphazene (PCPP) can be synthesized, which is cross-linked with dissolved multivalent cations in aqueous media at room temperature or below to form hydrogel matrices. Bioerodible polyphosphazenes have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze under in vivo conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl . The term bioerodible or biodegrable, as used herein, means a polymer that dissolves or degrades within a period that is acceptable in the desired application (usually in vivo therapy) , less than about five years and most preferably less than about one year, once exposed to a physiological solution of pH 6-8 having a temperature of between about 25°C and 38°C. Hydrolysis of the side chain results in erosion of the polymer. Examples of hydrolyzing side chains are unsubstituted and substituted imidizoles and amino acid esters in which the group is bonded to the phosphorous atom through an amino linkage (polyphosphazene polymers in which both R groups are attached in this manner are known as polyaminophosphazenes) . For polyimidazolephosphazenes, some of the "R" groups on the polyphosphazene backbone are imidazole rings, attached to phosphorous in the backbone through a ring nitrogen atom. Other "R" groups can be organic residues that do not participate in hydrolysis, such as methyl phenoxy groups or other groups shown in the scientific paper of Allcock, et al., Macromolecule 10:824-830 (1977) .
Methods for synthesis and the analysis of various types of polyphosphazenes are described by
Allcock, H.R.; et al . , Inorσ. Chem. 11, 2584 (1972) ; Allcock, et al . , Macromolecules 16, 715 (1983) ; Allcock, et al. , Macromolecules 19, 1508 (1986) ; Allcock, et al. , Bio aterials, 19, 500 (1988) ; Allcock, et al . , Macromolecules 21, 1980 (1988) ; Allcock, et al . , Inorσ. Chem. 21(2) , 515- 521 (1982) ; Allcock, et al . , Macromolecules 22, 75 (1989) ; U.S. Patent Nos. 4,440,921, 4,495,174 and 4,880,622 to Allcock, et al. ; U.S. Patent No. 4,946,938 to Magill, et al . ; and Grolleman, et al . , J. Controlled Release 3, 143 (1986) , the teachings of which are specifically incorporated herein by reference.
Methods for the synthesis of the other polymers described above are known to those skilled in the art. See, for example Concise Encyclopedia of Polymer Science and Polymeric Amines and
Ammonium Salts, E. Goethals, editor (Pergamen Press, Elmsford, NY 1980) . Many polymers, such as poly(acrylic acid) , are commercially available. The water soluble polymer with charged side groups is crosslinked by reacting the polymer with an aqueous solution containing multivalent ions of the opposite charge, either multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups. The preferred cations for cross-linking of the polymers with acidic side groups to form a hydrogel are divalent and trivalent cations such as copper, calcium, aluminum, magnesium, strontium, barium, and tin, although di-, tri- or tetra- functional organic cations such as alkylammonium salts, e.g., R3N* -\/\/\/-+NR3 can also be used. Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes. The higher the concentration of cation, or the higher the valence, the greater the degree of cross-linking of the polymer. Concentrations from as low as 0.005 M have been demonstrated to cross-link the polymer. Higher concentrations are limited by the solubility of the salt.
The preferred anions for cross-linking of the polymers to form a hydrogel are divalent and trivalent anions such as low molecular weight dicarboxylic acids, for example, terepthalic acid, sulfate ions and carbonate ions. Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.
A variety of polycations can be used to complex and thereby stabilize the polymer hydrogel into a semi-permeable surface membrane. Examples of materials that can be used include polymers having basic reactive groups such as amine or imine groups, having a preferred molecular weight between 3,000 and 100,000, such as polyethylenimine and polylysine. These are commercially available. One polycation is poly(L-lysine) , examples of synthetic polyamines are: polyethyleneimine, poly(vinylamine) , and poly(allyl amine) . There are also natural polycations such as the polysaccharide, chitosan. Polyanions that can be used to form a semi-permeable membrane by reaction with basic surface groups on the polymer hydrogel include polymers and copolymers of acrylic acid, methacrylic acid, and other derivatives of acrylic acid, polymers with pendant S03H groups such as sulfonated polystyrene, and polystyrene with carboxylic acid groups.
Method for Making Cell Suspensions The polymer is dissolved in an aqueous solution, preferably a 0.1 M potassium phosphate solution, at physiological pH, to a concentration forming a polymeric hydrogel, for example, for alginate, of between 0.5 to 2% by weight, preferably 1%, alginate. The isolated cells are suspended in the polymer solution to a concentration of between 1 and 50 million cells/ml, most preferably between 10 and 20 million cells/ml. Polymeric Matrix
Matrix Configuration For an organ to be constructed, successfully implanted, and function, the matrices must have sufficient surface area and exposure to nutrients such that cellular growth and differentiation can occur prior to the ingrowth of blood vessels following implantation. The time required for successful implantation and growth of the cells within the matrix is greatly reduced if the area into which the matrix is implanted is prevascularized. After implantation, the configuration must allow for diffusion of nutrients and waste products and for continued blood vessel ingrowth as cell proliferation occurs.
The organization of the tissue may be regulated by the microstructure of the matrix. Specific pore sizes and structures may be utilized to control the pattern and extent of fibrovascular tissue ingrowth from the host, as well as the organization of the implanted cells. The surface geometry and chemistry of the matrix may be regulated to control the adhesion, organization, and function of implanted cells or host cells. In the preferred embodiment, the matrix is formed of polymers having a fibrous structure which has sufficient interstitial spacing to allow for free diffusion of nutrients and gases to cells attached to the matrix surface. This spacing is typically in the range of 100 to 300 microns, although closer spacings can be used if the matrix is implanted, blood vessels allowed to infiltrate the matrix, then the cells are seeded into the matrix. As used herein, "fibrous" includes one or more fibers that is entwined with itself, multiple fibers in a woven or non-woven mesh, and sponge like devices.
Cells can either be implanted after seeding onto a matrix or injected into a matrix already implanted at the desired site. The latter has the advantage that the matrix can be used to prevascularize the site. In this case, the design and construction of the scaffolding is of primary importance. The matrix should be a pliable, non- toxic, injectable porous template for vascular ingrowth. The pores should allow vascular ingrowth and the injection of cells such as muscle cells without damage to the cells or patient. These are generally interconnected pores in the range of between approximately 100 and 300 microns. The matrix should be shaped to maximize surface area, to allow adequate diffusion of nutrients and growth factors to the cells and to allow the ingrowth of new blood vessels and connective tissue. At the present time, a porous structure that is resistant to compression is preferred for implantation, prevascularization, followed by seeding.
In the embodiment where the matrix is prevascularized, it may be desirable to incorporate into the matrix means for dispersing the cells throughout the matrix, for example, using catheters which can be removed following seeding.
The overall, or external, matrix configuration is dependent on the tissue which is to reconstructed or augmented. In most cases, the cell-matrix structure will be similar to the silicone implants now used, which are essentially disks that deform due to gravity to form a teardrop shape. The shape can also be obtained using struts, as described below, to impart resistance to mechanical forces and thereby yield the desired shape. The shape of the matrix per se will not be disk shaped, but will appear disk shaped when seeded with the cells to be implanted, or will create the outline of a disk or tear drop shape following implantation. Polymers Either natural or synthetic polymers can be used to form the matrix, although synthetic polymers are preferred for reproducibility and controlled release kinetics. Synthetic polymers that can be used include bioerodible polymers such as poly(lactide) (PLA) , poly(glycolic acid) (PGA) , poly(lactide-co-glycolide) (PLGA) , poly(caprolactone) , polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole) , chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, teflon®, and nylon. Although non-degradable materials can be used to form the matrix or a portion of the matrix, they are not preferred. The preferred non-degradable material for implantation of a matrix which is prevascularized prior to implantation of dissociated cells is a polyvinyl alcohol sponge, or alkylation, and acylation derivatives thereof, including esters. A non- absorbable polyvinyl alcohol sponge is available commercially as Ivalon™, from Unipoint Industries. Methods for making this material are described in U.S. Patent Nos. 2,609,347 to Wilson; 2,653,917 to Hammon, 2,659,935 to Hammon, 2,664,366 to Wilson, 2,664,367 to Wilson, and 2,846,407 to Wilson, the teachings of which are incorporated by reference herein. These materials are all commercially available.
Examples of natural polymers include proteins such as albumin, collagen, synthetic polyamino acids, and prolamines, and polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units.
PLA, PGA and PLA/PGA copolymers are particularly useful for forming the biodegradable matrices. PLA polymers are usually prepared from the cyclic esters of lactic acids. Both L(+) and D(-) forms of lactic acid can be used to prepare the PLA polymers, as well as the optically inactive DL-lactic acid mixture of D(-) and L(+) lactic acids. Methods of preparing polylactides are well documented in the patent literature. The following
U.S. Patents, the teachings of which are hereby incorporated by reference, describe in detail suitable polylactides, their properties and their preparation: 1,995,970 to Dorough; 2,703,316 to Schneider; 2,758,987 to Salzberg; 2,951,828 to Zeile; 2,676,945 to Higgins; and 2,683,136; 3, 531,561 to Trehu.
PGA is the homopolymer of glycolic acid (hydroxyacetic acid) . In the conversion of glycolic acid to poly(glycolic acid), glycolic acid is initially reacted with itself to form the cyclic ester glycolide, which in the presence of heat and a catalyst is converted to a high molecular weight linear-chain polymer. PGA polymers and their properties are described in more detail in Cyanamid
Research Develops World's First Synthetic Absorbable Suture", Chemistry and Industry, 905 (1970) .
The erosion of the matrix is related to the molecular weights of PLA, PGA or PLA/PGA. The higher molecular weights, weight average molecular weights of 90,000 or higher, result in polymer matrices which retain their structural integrity for longer periods of time; while lower molecular weights, weight average molecular weights of 30,000 or less, result in both slower release and shorter matrix lives. A preferred material is poly(lactide-co-glycolide) (50:50), which degrades in about six weeks following implantation (between one and two months) . All polymers for use in the matrix must meet the mechanical and biochemical parameters necessary to provide adequate support for the cells with subsequent growth and proliferation. The polymers can be characterized with respect to mechanical properties such as tensile strength using an Instron tester, for polymer molecular weight by gel permeation chromatography (GPC) , glass transition temperature by differential scanning calorimetry (DSC) and bond structure by infrared (IR) spectroscopy, with respect to toxicology by initial screening tests involving Ames assays and in vi tro teratogenicity assays, and implantation studies in animals for immunogenicity, inflammation, release and degradation studies. Polymer Coatings
In some embodiments, attachment of the cells to the polymer is enhanced by coating the polymers with compounds such as basement membrane components, agar, agarose, gelatin, gum arabic, collagens types I, II, III, IV, and V, fibronectin, laminin, glycosaminoglycans, polyvinyl alcohol, mixtures thereof, and other hydrophilic and peptide attachment materials known to those skilled in the art of cell culture. A preferred material for coating the polymeric matrix is polyvinyl alcohol or collagen. Struts
In some embodiments it may be desirable to create additional structure using devices provided for support, referred to herein as "struts". These can be biodegradable or non- degradable polymers which are inserted to form a more defined shape than is obtained using the cell- matrices, especially the hydrogel-cell suspensions. An analogy can be made to a corset, with the struts acting as "stays" to push the surrounding tissue and skin up and away from the implanted cells. In a preferred embodiment, the struts are implanted prior to or at the time of implantation of the cell-matrix structure. The struts are formed of a polymeric material of the same type as can be used to form the matrix, as listed above, having sufficient strength to resist the necessary mechanical forces.
Tissue Expanders Alternatively, or in addition, tissue expanders can be used to create additional space for implantation of cell-matrix structures. Tissue expanders are commercially available and routinely used for expansion of skin, for example, prior to plastic surgery, as reviewed by Cohen, J. Dermatol . Surα. Oncol. 19:614-615 (1993) , Bennett and Hirt, J. Dermatol. Surer. Oncol. 19:1066-1073 (1993) , Hammond, et al. , Plastic and Reconstructive Surgery, 92 (2) :255-259 (1993) , Walton and Brown, Annals of Plastic Surgery 30(2), 105-110 (February 1993), Kenna, et al. , Annals of Plastic Surgery 32, 346-349 (1994) , the teachings of which are incorporated herein. When skin is tensioned for long periods of time, weeks to months, it responds by a very significant stretching. This is associated with metabolic activity and tissue growth. The generally accepted definition of a tissue expander is a device that resides beneath the surface of the skin which is used to stretch the skin. A spherical tissue expander is a multi¬ dimensional expander, typically applied by volumetrically expanding a subcutaneous space with an inflatable device. Alternatively, multiple bolus materials can be implanted and the device shrunk or replaced through removal of one or more of the bolus materials.
The use of tissue expanders in breast reconstruction are well understood (see, for example, Hammond, et al., 1993) . Several different types of anatomically oriented or shaped expanders have been designed to give a more natural contour to the reconstructed breast . Devices are commercially available, for example, from McGhan Medical Corporation, Santa Barbara, CA, Dow Coming-Wright, Arlington, TN, and Mentor Corporation, Goleta, GA.
It is important to remove pressure from the implanted cells which can kill the cells. For example, in one preferred embodiment described in more detail below, a hydrogel-cell suspension is injected into the area where tissue is to be created. The space for injection of the cell- polymer suspension is created by implantation of a tissue expander prior to injection of the hydrogel- cell suspension. The tissue expander is inflated or expanded through implantation of a desired number of modules, to maximize the space and skin required for formation of tissue. As shown in detail in Figures 3A, 3B, and 3C, each time cell- matrix is injected, the tissue expander is deflated or a module is removed to leave a space of an equivalent amount to the volume of cell-matrix injected. Once the space is essentially filled with new tissue or cell-matrix suspension, ' the tissue expander is removed, using in most cases a local anesthetic and minor incision.
Additives to Polymer Matrices In some embodiments it may be desirable to add bioactive molecules to the cells. A variety of bioactive molecules can be delivered using the matrices described herein. These are referred to generically herein as "factors" or "bioactive factors" .
In the preferred embodiment, the bioactive factors are growth factors, angiogenic factors, compounds selectively inhibiting ingrowth of fibroblast tissue such as antiinflammatories, and compounds selectively inhibiting growth and proliferation of transformed (cancerous) cells. These factors may be utilized to control the growth and function of implanted cells, the ingrowth of blood vessels into the forming tissue, and/or the deposition and organization of fibrous tissue around the implant. Examples of growth factors include heparin binding growth factor (hbgf) , transforming growth factor alpha or beta (TGF/S) , alpha fibroblastic growth factor (FGF) , epidermal growth factor (TGF) , vascular endothelium growth factor (VEGF) , some of which are also angiogenic factors. Other factors include hormones such as insulin, glucagon, and estrogen. In some embodiments it may be desirable to incorporate factors such as nerve growth factor (NGF) or muscle morphogenic factor (MMP) .
Steroidal antiinflammatories can be used to decrease inflammation to the implanted matrix, thereby decreasing the amount of fibroblast tissue growing into the matrix.
Where selective chemotherapeutic agents are available which do not inhibit growth of normal cells, such as antibody targeted chemotherapeutic agents, these can be incorporated into the matrix and used to inhibit any residual cancer cells remaining following a mastectomy.
These factors are known to those skilled in the art and are available commercially or described in the literature. In vivo dosages are calculated based on in vi tro release studies in cell culture; an effective dosage is that dosage which increases cell proliferation or survival as compared with controls, as described in more detail in the following examples. Preferably, the bioactive factors are incorporated to between one and 30% by weight, although the factors can be incorporated to a weight percentage between 0.01 and 95 weight percentage.
Bioactive molecules can be incorporated into the matrix and released over time by diffusion and/or degradation of the matrix, they can be suspended with the cell suspension, they can be incorporated into microspheres which are suspended with the cells or attached to or incorporated within the matrix, or some combination thereof. Microspheres would typically be formed of materials similar to those forming the matrix, selected for their release properties rather than structural properties. Release properties can also be determined by the size and physical characteristics of the microspheres. Suitable microspheres and methods for their use in tissue generation is described in U.S. Serial No. 08/358,235 by David J. Mooney, Robert S. Langer, and Joseph P. Vacanti, entitled "Localized Delivery of Factors Enhancing Survival of Transplanted Cells", co-filed herewith in the U.S. Patent and Trademark Office on December 16, 1994, the teachings of which are incorporated herein.
III. Methods for Implantation
As discussed generally above, there are three methods which can be used to create new breast tissue. These can be used alone or in various combinations. Variations include where the cell, which can be a hydrogel solution or a solid fibrous matrix, before implantation or serially introduced after matrix implantation to allow pre- vascularization of the matrix. The form of the engineered tissue can be regulated by utilizing a tissue expander to create the desired space for tissue formation, and then serially deflating the tissue expander while the cells of interest are delivered to this newly created space. This allows the tissue form to be pre-defined, and allows serial introduction of cells for form new tissue. Alternatively, a pre-formed matrix can be implanted, allowed to vascularize, then be seeded with dissociated cells which form new tissue, preferably as the matrix degrades. Selection of the appropriate system depends on the degree of augmentation required, and determines whether the whole injection can be performed at once, or alternatively, performed in a sequential manner, so as to allow for tissue formation with adequate vascularization before subsequent injections are performed.
Selection of cell type can be used to vary the texture of the implanted material, as well as the appearance. For example, cartilage can be used, if a more rigid implant is desired. In some embodiments it may be desirable to create softer tissue, for example, using adipocytes or other soft tissue components.
Figure 1 is a schematic of the process for implantation of dissociated cells 10 on a polymeric matrix 12 into breast 14 for breast tissue augmentation. The cells attach to the matrix 12, which is originally disk shaped but deforms to a tear drop shape when implanted. As vascularization occurs and the matrix degrades, new tissue is formed.
Figure 2 is a schematic of a fibrous plate 20 implanted into breast tissue 22 with struts 24 to provide support of surrounding tissue and skin and allow new tissue to be formed within the strut following injection of a cell-hydrogel suspension (not shown) .
Figures 3A, 3B and 3C are schematics of the serial injection of a cell-hydrogel suspension following implantation of a tissue expander (Figure 3A) , with the tissue expander being decreased in size each time the suspension is injected (Figure 3B) , so that new tissue forms in the space left as the expander is decreased in volume (Figure 3C) .

Claims

We claim :
1. A method for augmentation or reconstruction of breast tissue comprising implanting an effective amount of dissociated cells selected from the group consisting of mesenchymal cells, myocytes, chondrocytes, adipocytes, fibromyoblasts, ectodermal cells, and nerve cells, to form breast tissue.
2. The method of claim 1 wherein the cells are smooth or skeletal muscle cells.
3. The method of claim 1 further comprising implanting the cells in combination with a matrix.
4. The method of claim 3 wherein the matrix is a biocompatible, biodegradable hydrogel.
5. The method of claim 3 wherein the matrix is implanted, allowed to vascularize, then seeded with cells.
6. The method of claim 3 wherein the matrix is a fibrous, polymeric matrix.
7. The method of claim 3 wherein the matrix is formed of a biodegradable polymer.
8. The method of claim 3 further comprising implanting struts with the matrix that support the surrounding tissue.
9. The method of claim 1 further comprising implanting bioactive molecules selected from the group of molecules enhancing vascularization, cell survival, proliferation or differentiation, inhibiting ingrowth of fibrotic tissue, inhibiting growth of cancerous cells, and inhibiting inflammation.
10. The method of claim 1 further comprising implanting a tissue expander prior to implanting cells in combination with a matrix, then implanting cells in combination with matrix each time the expander is decreased in size.
11. A composition for augmenting or reconstructing breast tissue comprising dissociated cells selected from the group consisting of mesenchymal cells, myocytes, chondrocytes, adipocytes, fibromyoblasts, ectodermal cells, and nerve cells in combination with a fibrous polymeric matrix, where the combination of the cells and matrix is effective to augment or reconstruct breast tissue.
12. The composition of claim 11 wherein the cells are smooth or skeletal muscle cells.
13. The composition of claim 11 wherein the fibrous matrix has a disk or tear drop shape.
14. The composition of claim 11 further comprising struts that support the surrounding tissue.
15. The composition of claim 11 further comprising bioactive molecules selected from the group of molecules enhancing vascularization, cell survival, proliferation or differentiation, inhibiting ingrowth of fibrotic tissue, inhibiting growth of cancerous cells, and inhibiting inflammation.
16. The composition of claim 11 further comprising a tissue expander.
17. The composition of claim 11 wherein the matrix is suitable for implantation and vascularization prior to seeding with cells, characterized by means for dispersing the cells throughout the matrix following implantation and being resistant to compression.
18. The composition of claim 11 wherein the matrix is formed of biodegradable polymers.
PCT/US1995/016424 1994-12-16 1995-12-15 Breast tissue engineering WO1996018424A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002207757A CA2207757C (en) 1994-12-16 1995-12-15 Breast tissue engineering
EP95943847A EP0797460B1 (en) 1994-12-16 1995-12-15 Breast tissue engineering
AT95943847T ATE290892T1 (en) 1994-12-16 1995-12-15 BREAST TISSUE TECHNOLOGY
JP8519297A JPH10510736A (en) 1994-12-16 1995-12-15 Chest tissue strengthening technology
DE69534083T DE69534083T2 (en) 1994-12-16 1995-12-15 BREAST TISSUE TECHNOLOGY
MX9704454A MX9704454A (en) 1994-12-16 1995-12-15 Breast tissue engineering.
AU45217/96A AU717861B2 (en) 1994-12-16 1995-12-15 Breast tissue engineering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/358,189 US5716404A (en) 1994-12-16 1994-12-16 Breast tissue engineering
US358,189 1994-12-16

Publications (1)

Publication Number Publication Date
WO1996018424A1 true WO1996018424A1 (en) 1996-06-20

Family

ID=23408629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016424 WO1996018424A1 (en) 1994-12-16 1995-12-15 Breast tissue engineering

Country Status (9)

Country Link
US (1) US5716404A (en)
EP (1) EP0797460B1 (en)
JP (1) JPH10510736A (en)
AT (1) ATE290892T1 (en)
AU (1) AU717861B2 (en)
CA (1) CA2207757C (en)
DE (1) DE69534083T2 (en)
MX (1) MX9704454A (en)
WO (1) WO1996018424A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025396A2 (en) * 1997-11-17 1999-05-27 The Regents Of The University Of Michigan Hybrid tissues for tissue engineering
WO1999022677A3 (en) * 1997-10-31 1999-07-08 Childrens Medical Center Penile reconstruction
WO2000033771A2 (en) * 1998-12-11 2000-06-15 Johnson Gerald W Implants filled with solid or semi-solid material
WO2000044882A2 (en) * 1999-01-29 2000-08-03 Zen-Bio, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
US6582960B1 (en) 1998-09-18 2003-06-24 Massachusetts Institute Of Technology Use of fibroblast growth factor 2 for expansion of chondrocytes and tissue engineering
EP1335735A1 (en) * 2000-08-21 2003-08-20 Bernard O'Brien Institute of Microsurgery Vascularised tissue graft
WO2005021737A1 (en) 2003-09-01 2005-03-10 Aivogen Ag Follicular fluid for prolonged growth and survival of cells for cell therapies
EP2350274A2 (en) * 2008-10-21 2011-08-03 The General Hospital Corporation Cell transplantation
US7998735B2 (en) 2000-08-21 2011-08-16 Victorian Tissue Engineering Centre Pty. Ltd. Vascularized tissue graft
GB2526542A (en) * 2014-05-26 2015-12-02 David Anthony Waghorn Stem cell implanter and absorbable stem cell implant
US9314420B2 (en) 2005-10-26 2016-04-19 Jan-Eric Ahlfors Acellular bioabsorbable tissue regeneration matrices
EP3060060A4 (en) * 2013-10-25 2017-08-23 Collins, Scott Forrest Tissue engineered devices and methods for making same
US10022486B2 (en) 2011-06-24 2018-07-17 Gearbox, Llc Device, system, and method including micro-patterned cell treatment array
US10184110B2 (en) 2010-08-06 2019-01-22 The General Hospital Corporation System and apparatus for cell treatment
WO2019081708A1 (en) 2017-10-26 2019-05-02 Carl Freudenberg Kg Biocompatible soft tissue implant
US10799336B2 (en) 2014-09-09 2020-10-13 Klinikum Rechts Der Isar Der Technischen Universität München Medical/surgical implant

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352707B1 (en) 1992-02-24 2002-03-05 Anton-Lewis Usala Transplant encapsulation in a hydrogel matrix to obscure immune recognition
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US6334872B1 (en) 1994-02-18 2002-01-01 Organogenesis Inc. Method for treating diseased or damaged organs
DE69534233T2 (en) * 1994-09-16 2005-10-27 Ethicon Endo-Surgery, Inc., Cincinnati DEVICES FOR DETERMINING AND MARKING TISSUE
US6123727A (en) * 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
WO1998036704A1 (en) * 1997-02-20 1998-08-27 Keller Gregory S Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US8288745B2 (en) * 1997-10-10 2012-10-16 Senorx, Inc. Method of utilizing an implant for targeting external beam radiation
EP1032435B1 (en) * 1997-10-31 2003-09-03 Children's Medical Center Corporation Bladder reconstruction
US6270464B1 (en) 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
US6872387B1 (en) 1998-02-24 2005-03-29 The Regents Of The University Of Michigan Three-dimensional hydrogel/cell system
US6660301B1 (en) * 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
AU3552099A (en) * 1998-04-09 1999-11-01 Charlotte-Mecklenburg Hospital Authority Creation of three-dimensional tissues
US6027744A (en) * 1998-04-24 2000-02-22 University Of Massachusetts Medical Center Guided development and support of hydrogel-cell compositions
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
WO1999059506A1 (en) * 1998-05-21 1999-11-25 Children's Medical Center Corporation Corporal tissue penile reconstruction
US6224630B1 (en) 1998-05-29 2001-05-01 Advanced Bio Surfaces, Inc. Implantable tissue repair device
EP1083843A4 (en) * 1998-06-05 2005-06-08 Organogenesis Inc Bioengineered vascular graft support prostheses
EP1082057B1 (en) * 1998-06-05 2009-02-25 Organogenesis Inc. Bioengineered tubular graft prostheses
AU754838B2 (en) * 1998-06-05 2002-11-28 Organogenesis Inc. Bioengineered flat sheet graft prostheses
WO1999062425A2 (en) * 1998-06-05 1999-12-09 Organogenesis Inc. Bioengineered vascular graft prostheses
US20020058882A1 (en) * 1998-06-22 2002-05-16 Artemis Medical, Incorporated Biopsy localization method and device
US6206930B1 (en) 1998-08-10 2001-03-27 Charlotte-Mecklenburg Hospital Authority Absorbable tissue expander
US6723133B1 (en) * 1998-09-11 2004-04-20 C. R. Bard, Inc. Performed curved prosthesis having a reduced incidence of developing wrinkles or folds
US6740122B1 (en) 1998-09-11 2004-05-25 C. R. Bard, Inc. Preformed curved prosthesis that is adapted to the external iliac vessels
DK1131410T3 (en) * 1998-11-19 2005-10-31 Organogenesis Inc Genetic tissue structures and processes for their preparation and use
US9669113B1 (en) 1998-12-24 2017-06-06 Devicor Medical Products, Inc. Device and method for safe location and marking of a biopsy cavity
US6371904B1 (en) * 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6356782B1 (en) * 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6197061B1 (en) * 1999-03-01 2001-03-06 Koichi Masuda In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage
US20040167634A1 (en) * 1999-05-26 2004-08-26 Anthony Atala Prosthetic kidney and its use for treating kidney disease
DE60031114T2 (en) 1999-06-11 2007-05-03 Cytyc Corp., Marlborough LIQUID GEL FORMULATION FOR DETECTING MILK CHANNELS IN THE CHEST BEFORE SURGICAL ABLATION OF THE BREAST TISSUE
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US6371984B1 (en) * 1999-09-13 2002-04-16 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US7951201B2 (en) * 1999-10-20 2011-05-31 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US20030153976A1 (en) * 1999-10-20 2003-08-14 Cauthen Joseph C. Spinal disc annulus reconstruction method and spinal disc annulus stent
US7052516B2 (en) * 1999-10-20 2006-05-30 Anulex Technologies, Inc. Spinal disc annulus reconstruction method and deformable spinal disc annulus stent
US8632590B2 (en) * 1999-10-20 2014-01-21 Anulex Technologies, Inc. Apparatus and methods for the treatment of the intervertebral disc
US6592625B2 (en) 1999-10-20 2003-07-15 Anulex Technologies, Inc. Spinal disc annulus reconstruction method and spinal disc annulus stent
US8128698B2 (en) 1999-10-20 2012-03-06 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US20020123807A1 (en) * 1999-10-20 2002-09-05 Cauthen Joseph C. Spinal disc annulus reconstruction method and spinal disc annulus stent
US7935147B2 (en) 1999-10-20 2011-05-03 Anulex Technologies, Inc. Method and apparatus for enhanced delivery of treatment device to the intervertebral disc annulus
US7004970B2 (en) 1999-10-20 2006-02-28 Anulex Technologies, Inc. Methods and devices for spinal disc annulus reconstruction and repair
US7615076B2 (en) * 1999-10-20 2009-11-10 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) * 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
AU2001247507A1 (en) 2000-03-20 2001-10-03 Biosphere Medical, Inc. Injectable microspheres for tissue construction
WO2001070289A2 (en) 2000-03-20 2001-09-27 Biosphere Medical, Inc. Injectable and swellable microspheres for tissue bulking
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US6436424B1 (en) * 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE01918975T1 (en) 2000-03-24 2006-04-13 Biosphere Medical, Inc., Rockland Microspheres for active embolization
DE10026480A1 (en) * 2000-05-29 2001-12-13 Augustinus Bader Method of making a recipient-specific tissue graft or implant
AU2001265151A1 (en) 2000-05-31 2001-12-11 Encelle, Inc. Method of stimulating hair growth
US6991652B2 (en) * 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
CA2777791A1 (en) * 2000-09-18 2002-03-21 Organogenesis Inc. Methods for treating a patient using a bioengineered flat sheet graft prostheses
US20020151050A1 (en) * 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
US6656488B2 (en) 2001-04-11 2003-12-02 Ethicon Endo-Surgery, Inc. Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering
DE10119522A1 (en) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Preparation and application of a suspension composition with an ultrasound contrast medium
US7476257B2 (en) 2001-09-15 2009-01-13 Rush University Medical Center Methods to engineer stratified cartilage tissue
KR20030032420A (en) * 2001-10-18 2003-04-26 한국과학기술연구원 Porous Scaffold Made of Biodegradable Polymer for Reconstructing Damaged Ocular Tissue
US7722894B2 (en) * 2001-10-22 2010-05-25 Massachusetts Institute Of Technology Biodegradable polymer
US20030165473A1 (en) * 2001-11-09 2003-09-04 Rush-Presbyterian-St. Luke's Medical Center Engineered intervertebral disc tissue
BR0214217A (en) * 2001-11-16 2004-09-21 Childrens Medical Center Increased Organ Function
US20080086792A1 (en) 2006-10-13 2008-04-17 Thomas Charles Kuracina Method and apparatus for diverting sweat, liquid, moisture or the like from an eye
AU2003215330B2 (en) 2002-02-21 2008-03-13 Encelle, Inc. Immobilized bioactive hydrogel matrices as surface coatings
US7396537B1 (en) * 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
CA2485259A1 (en) * 2002-05-07 2003-11-20 Mcmaster University Microcapsules containing biomedical materials
US20050019747A1 (en) * 2002-08-07 2005-01-27 Anderson Daniel G. Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US20040028804A1 (en) * 2002-08-07 2004-02-12 Anderson Daniel G. Production of polymeric microarrays
EP2392359A3 (en) 2002-08-12 2012-03-07 Warsaw Orthopedic, Inc. Synthesis of a bone-polymer composite material
US20040042997A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of regenerating human tissue
US20040136968A1 (en) * 2002-09-27 2004-07-15 Verigen Ag Autologous cells on a support matrix for tissue repair
WO2004034890A2 (en) * 2002-10-17 2004-04-29 Vacanti, Joseph, P. Biological scaffolding material
KR100539371B1 (en) * 2002-10-21 2005-12-27 메디칸(주) In vitro cultured human preadipocyte for human soft tissue volume replacement with injectable material as a scaffold
WO2004039248A2 (en) * 2002-10-31 2004-05-13 The General Hospital Corporation Repairing or replacing tissues or organs
CA2511486A1 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
DE20306637U1 (en) * 2003-04-28 2003-06-26 Gfe Medizintechnik Gmbh Soft tissue implants such as breast implants, calf muscle prosthesis or the like.
US8092527B2 (en) * 2003-09-03 2012-01-10 Brennan William A System and method for breast augmentation
US7169180B2 (en) * 2003-09-03 2007-01-30 Brennan William A System and method for breast augmentation
US20050136536A1 (en) * 2003-09-15 2005-06-23 Anderson Daniel G. Embryonic epithelial cells
JP2007521114A (en) * 2003-12-10 2007-08-02 ハンク・シー・ケイ・ウー Methods and compositions for reconstruction of soft tissue features
US8012210B2 (en) * 2004-01-16 2011-09-06 Warsaw Orthopedic, Inc. Implant frames for use with settable materials and related methods of use
US20060015184A1 (en) * 2004-01-30 2006-01-19 John Winterbottom Stacking implants for spinal fusion
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
US7273756B2 (en) * 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8017394B2 (en) * 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7754241B1 (en) 2004-11-12 2010-07-13 Clemson University Research Foundation Macromonomer for preparation of a degradable hydrogel
AT501408B1 (en) 2004-12-07 2011-03-15 Physikalisches Buero Steinmueller Gmbh BIOLOGICAL SURFACES
DE602005022481D1 (en) * 2004-12-08 2010-09-02 Pervasis Therapeutics Inc COMPOSITIONS AND THEIR USE FOR BETTER VESSEL ACCESS
US9788978B2 (en) * 2004-12-20 2017-10-17 Nicholas A. Rojo Implantable systems and stents containing cells for therapeutic uses
JP2008531769A (en) * 2005-02-23 2008-08-14 ズィマー・テクノロジー・インコーポレーテッド Blend hydrogel and method for producing the same
JP5174656B2 (en) * 2005-04-21 2013-04-03 マサチューセッツ インスティテュート オブ テクノロジー Materials and methods for modifying an immune response against exogenous and endogenous immunogens, including syngeneic or non-syngeneic cells, tissues or organs
CN104815331A (en) 2005-05-09 2015-08-05 生物领域医疗公司 Compositions and methods using microspheres and non-ionic contrast agents
CN102743792B (en) 2005-06-21 2014-09-24 夏尔再生医学公司 Methods and compositions for enhancing vascular access
US20070042491A1 (en) * 2005-08-18 2007-02-22 Karp Jeffrey M Amplification of cell populations from embryonic stem cells
WO2007055882A2 (en) * 2005-11-07 2007-05-18 Hosheng Tu Breast augmentation and reconstruction system
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
AU2006321809A1 (en) 2005-12-07 2007-06-14 Zimmer, Inc. Methods of bonding or modifying hydrogels using irradiation
US9267937B2 (en) * 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8017107B2 (en) 2005-12-22 2011-09-13 Zimmer, Inc. Perfluorocyclobutane crosslinked hydrogels
WO2007082304A2 (en) 2006-01-12 2007-07-19 Massachusetts Institute Of Technology Biodegradable elastomers
US20090011486A1 (en) * 2006-01-12 2009-01-08 Massachusetts Institute Of Technology Biodegradable Elastomers
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
EP1976459A4 (en) * 2006-01-19 2012-06-20 Warsaw Orthopedic Inc Porous osteoimplant
WO2007084725A2 (en) * 2006-01-19 2007-07-26 Osteotech, Inc. Injectable and moldable bone substitute materials
US8110242B2 (en) 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20080193536A1 (en) * 2006-08-14 2008-08-14 Alireza Khademhosseini Cell-Laden Hydrogels
US7846728B2 (en) * 2006-10-13 2010-12-07 BioStruxs, LLC Tissue engineering in vivo with vascularized scaffolds
SG176460A1 (en) * 2006-11-07 2011-12-29 Pervasis Therapeutics Inc Materials and methods for treating and managing angiogenesis-mediated diseases
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
EP2109641B1 (en) * 2007-01-17 2017-03-01 AgroFresh Inc. Delivery of ethylene blocking and/or promoting agents
WO2008098165A2 (en) * 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008144514A2 (en) * 2007-05-17 2008-11-27 Massachusetts Institute Of Technology Polyol-based polymers
US9199002B2 (en) * 2007-05-24 2015-12-01 The Trustees Of Columbia University In The City Of New York Hybrid soft tissue implants from progenitor cells and biomaterials
ATE487441T1 (en) * 2007-06-01 2010-11-15 Allergan Inc DEVICE FOR GENERATING TENSILE-INDUCED GROWTH OF BIOLOGICAL TISSUE
KR101804287B1 (en) 2007-06-08 2017-12-04 웨이크 포리스트 유니버시티 헬스 사이언시즈 Selective cell therapy for the treatment of renal failure
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
EP2162283B1 (en) 2007-06-14 2015-08-12 Massachusetts Institute of Technology Self assembled films for protein and drug delivery applications
US20100291219A1 (en) * 2007-06-21 2010-11-18 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
US7731988B2 (en) * 2007-08-03 2010-06-08 Zimmer, Inc. Multi-polymer hydrogels
DE102007039871A1 (en) 2007-08-21 2009-02-26 Friedrich-Baur-Gmbh Soft tissue implant with antibacterial effect
US8293531B1 (en) 2007-08-31 2012-10-23 Clemson University Research Foundation Three-dimensional ex vivo system
US8062739B2 (en) 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
ES2376175T3 (en) 2007-09-28 2012-03-09 Bind Biosciences, Inc. ADDRESS TO CELL? NCER CELLS USING NANOPART�? CULAS.
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
US7947784B2 (en) 2007-11-16 2011-05-24 Zimmer, Inc. Reactive compounding of hydrogels
WO2009069123A2 (en) 2007-11-26 2009-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions comprising fibrous polypeptides and polysaccharides
US20090181104A1 (en) * 2007-12-14 2009-07-16 Gino Rigotti Breast reconstruction or augmentation using computer-modeled deposition of processed adipose tissue
US8034362B2 (en) 2008-01-04 2011-10-11 Zimmer, Inc. Chemical composition of hydrogels for use as articulating surfaces
US20100082072A1 (en) * 2008-03-28 2010-04-01 Sybert Daryl R Bone anchors for orthopedic applications
WO2010003104A2 (en) * 2008-07-02 2010-01-07 Allergan, Inc. Compositions and methods for tissue filling and regeneration
WO2010021973A2 (en) * 2008-08-17 2010-02-25 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
WO2010022131A1 (en) 2008-08-20 2010-02-25 Allergan, Inc. Self-sealing shell for inflatable prostheses
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8163022B2 (en) 2008-10-14 2012-04-24 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
WO2010057015A1 (en) * 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
US9308070B2 (en) 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
US8673267B2 (en) 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
US20100249924A1 (en) * 2009-03-27 2010-09-30 Allergan, Inc. Bioerodible matrix for tissue involvement
US20110052695A1 (en) * 2009-04-20 2011-03-03 Allergan, Inc. Drug delivery platforms comprising silk fibroin hydrogels and uses thereof
US20110111031A1 (en) * 2009-04-20 2011-05-12 Guang-Liang Jiang Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
ES2423055T3 (en) * 2009-04-20 2013-09-17 Allergan, Inc. Silk fibroin hydrogels and uses of these
US20110189292A1 (en) * 2009-04-20 2011-08-04 Allergan, Inc. Dermal fillers comprising silk fibroin hydrogels and uses thereof
EA201791383A1 (en) 2009-05-27 2018-06-29 Селекта Байосайенсиз, Инк. NANOSEELS HAVE COMPONENTS WITH DIFFERENT RELEASE RATES
US9014787B2 (en) 2009-06-01 2015-04-21 Focal Therapeutics, Inc. Bioabsorbable target for diagnostic or therapeutic procedure
CN107617110A (en) 2009-08-26 2018-01-23 西莱克塔生物科技公司 The composition of inducing T cell auxiliary
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
JP2013510577A (en) 2009-11-12 2013-03-28 ブイビーアイ テクノロジーズ, エルエルシー Subpopulations of spore-like cells and their uses
KR101812820B1 (en) * 2010-01-08 2017-12-27 웨이크 포리스트 유니버시티 헬스 사이언시즈 Delivery system
US8460319B2 (en) 2010-01-11 2013-06-11 Anulex Technologies, Inc. Intervertebral disc annulus repair system and method
ES2729994T3 (en) 2010-03-22 2019-11-07 Allergan Inc Crosslinked polysaccharide and protein polysaccharide hydrogels for soft tissue augmentation
NO2575876T3 (en) 2010-05-26 2018-05-05
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8697056B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9549901B2 (en) 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
EP2683328B1 (en) 2011-03-07 2017-11-08 Wake Forest University Health Sciences Delivery system
ES2684949T3 (en) 2011-03-09 2018-10-05 Tepha, Inc. Mastopexy systems
EA201791679A1 (en) 2011-04-29 2018-09-28 Селекта Байосайенсиз, Инк. TOLEROGENIC SYNTHETIC NANO CARRIERS
CN102258810A (en) * 2011-07-20 2011-11-30 王泰华 Preparation method of adipose tissue breast augmentation material enriched with autologous stem cells
EP2736537A4 (en) 2011-07-29 2015-04-15 Selecta Biosciences Inc Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
WO2013020714A2 (en) 2011-08-11 2013-02-14 Qiagen Gmbh Cell- or virus simulating means comprising encapsulated marker molecules
CA2854160A1 (en) 2011-11-02 2013-05-10 Halscion, Inc. Methods and compositions for wound treatment
CA2861048C (en) * 2012-01-24 2021-01-12 Lifecell Corporation Elongated tissue matrices
EP2841056A4 (en) 2012-04-23 2015-09-16 Massachusetts Inst Technology Stable layer-by-layer coated particles
US20130289389A1 (en) 2012-04-26 2013-10-31 Focal Therapeutics Surgical implant for marking soft tissue
US20140017263A1 (en) 2012-06-28 2014-01-16 Clemson University Delivery Agents for Targeted Treatment of Elastin Degradation
US20140072611A1 (en) 2012-09-07 2014-03-13 Fibrocell Technologies, Inc. Methods and Compositions for Treating Post-Cardial Infarction Damage
US9737294B2 (en) 2013-01-28 2017-08-22 Cartiva, Inc. Method and system for orthopedic repair
AU2014209124A1 (en) 2013-01-28 2015-09-17 Cartiva, Inc. Systems and methods for orthopedic repair
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
US9867939B2 (en) 2013-03-12 2018-01-16 Allergan, Inc. Adipose tissue combinations, devices, and uses thereof
KR20150127206A (en) 2013-03-14 2015-11-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Nanoparticle-based compositions
WO2014150074A1 (en) 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
CN111686255A (en) 2013-05-03 2020-09-22 西莱克塔生物科技公司 Delivery of immunosuppressants and antigens with specific pharmacodynamic effective duration for induction of immune tolerance
US20140350516A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Mechanical syringe accessory
IL295392A (en) 2013-06-04 2022-10-01 Selecta Biosciences Inc Repeated administration of non-immunosupressive antigen specific immunotherapeutics
US9532867B2 (en) 2013-07-11 2017-01-03 Tepha, Inc. Absorbable implants for plastic surgery
CN104278008B (en) 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 Method, kit and application for preparing pluripotent stem cells through small molecule compound treatment
US9795573B2 (en) 2013-09-24 2017-10-24 Clemson University Multi-step connective tissue stabilization method and stabilized tissue formed thereby
US9248384B2 (en) 2013-10-02 2016-02-02 Allergan, Inc. Fat processing system
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
US11638640B2 (en) 2014-06-11 2023-05-02 Bard Shannon Limited In vivo tissue engineering devices, methods and regenerative and cellular medicine employing scaffolds made of absorbable material
US11883275B2 (en) 2014-06-11 2024-01-30 Bard Shannon Limited In vivo tissue engineering devices, methods and regenerative and cellular medicine employing scaffolds made of absorbable material
WO2015200728A1 (en) 2014-06-25 2015-12-30 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
ES2933054T3 (en) 2014-07-25 2023-01-31 Hologic Inc Implantable devices and techniques for oncoplastic surgery
MX2017002934A (en) 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses.
CN107072965B (en) 2014-11-05 2021-05-11 西莱克塔生物科技公司 Methods and compositions related to synthetic nanoparticles with rapamycin in a stable supersaturated state
EP3268063A4 (en) 2015-03-10 2018-10-31 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector
USD803401S1 (en) 2015-04-23 2017-11-21 Tepha, Inc. Three dimensional mastopexy implant
JP6780870B2 (en) 2015-08-13 2020-11-04 北昊干細胞与再生医学研究院有限公司Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Induced expanded pluripotent stem cells, how to make and use
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
USD836778S1 (en) 2015-10-09 2018-12-25 Tepha, Inc. Three dimensional mastopexy implant
US20190282624A1 (en) 2015-11-30 2019-09-19 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
WO2017117188A1 (en) 2015-12-29 2017-07-06 Massachusetts Institute Of Technology Biodegradable free-standing controlled drug release stickers
EP3416686A1 (en) 2016-02-16 2018-12-26 Dana Farber Cancer Institute, Inc. Immunotherapy compositions and methods
EP3426285A1 (en) 2016-03-11 2019-01-16 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
EP3439716B1 (en) 2016-04-08 2023-11-01 Allergan, Inc. Aspiration and injection device
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CA3038089A1 (en) 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
JP2020502062A (en) 2016-11-17 2020-01-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Alkylpyrrolopyrimidine analogs and methods of making and using same
JP2020506890A (en) 2017-01-07 2020-03-05 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. Patterned administration of immunosuppressants coupled to synthetic nanocarriers
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018187688A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
USD816220S1 (en) 2017-04-11 2018-04-24 Tepha, Inc. Three dimensional mastopexy implant
USD816221S1 (en) 2017-04-11 2018-04-24 Tepha, Inc. Three dimensional mastopexy implant
WO2018218480A1 (en) 2017-05-31 2018-12-06 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Methods for chemically induced lineage reprogramming
WO2019046818A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
US11219502B2 (en) 2017-09-11 2022-01-11 Medtronic Advanced Energy, Llc Transformative shape-memory polymer tissue cavity marker devices, systems and deployment methods
US20200249194A9 (en) 2017-10-12 2020-08-06 Massachusetts Institute Of Technology Prostate protease nanosensors and uses thereof
CA3078705A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2019104392A1 (en) * 2017-11-30 2019-06-06 Queensland University Of Technology Modular tissue implants
US11324567B2 (en) 2018-02-01 2022-05-10 Medtronic Advanced Energy, Llc Expandable tissue cavity marker devices, systems and deployment methods
USD889654S1 (en) 2018-02-09 2020-07-07 Tepha, Inc. Three dimensional mastopexy implant
USD889655S1 (en) 2018-02-09 2020-07-07 Tepha, Inc. Three dimensional mastopexy implant
EP4230178A1 (en) 2018-02-09 2023-08-23 Tepha, Inc. Full contour breast implant
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
US11883276B2 (en) 2018-03-12 2024-01-30 Bard Shannon Limited In vivo tissue engineering devices, methods and regenerative and cellular medicine employing scaffolds made of absorbable material
US20210115378A1 (en) 2018-05-09 2021-04-22 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
USD892329S1 (en) 2018-07-03 2020-08-04 Tepha, Inc. Three dimensional mastopexy implant
CA3106640A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
KR20210032438A (en) 2018-07-16 2021-03-24 셀렉타 바이오사이언시즈, 인크. Methods and compositions of OTC constructs and vectors
US20200096514A1 (en) 2018-09-25 2020-03-26 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020072349A1 (en) 2018-10-02 2020-04-09 Tepha, Inc. Medical devices to limit movement of breast implants
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
EP3867396A2 (en) 2018-10-16 2021-08-25 Massachusetts Institute of Technology Renal clearable nanocatalysts for disease monitoring
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
JP2022534741A (en) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド Methods and compositions for attenuated antiviral transduction vector immune response
CA3138071A1 (en) 2019-06-04 2020-12-10 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CA3158408A1 (en) 2019-10-21 2021-04-29 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
AU2020380944A1 (en) 2019-11-08 2022-06-02 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CN114980838A (en) 2019-11-25 2022-08-30 特法公司 Breast implant wrap to limit movement of breast implant and related methods
US20210262025A1 (en) 2020-02-18 2021-08-26 Massachusetts Institute Of Technology Multiplexed in vivo disease sensing with nucleic acid-barcoded reporters
MX2022010568A (en) 2020-02-26 2022-11-30 Selecta Biosciences Inc Methods and compositions using synthetic nanocarriers comprising immunosuppressant.
CN115484931A (en) 2020-03-11 2022-12-16 西莱克塔生物科技公司 Methods and compositions related to synthetic nanocarriers
JP2023519161A (en) 2020-03-23 2023-05-10 バード シャノン リミテッド In vivo tissue engineering devices, methods and regenerative and cell therapy using scaffolds made of absorbable materials
CN115698262A (en) 2020-03-30 2023-02-03 阿卜杜拉国王科技大学 Compositions and methods for controlling cell identity
JP2023530385A (en) 2020-04-14 2023-07-18 セレクタ バイオサイエンシーズ インコーポレーテッド Methods and compositions for inducing autophagy
US11413129B2 (en) 2020-06-19 2022-08-16 Davol Inc. Implantable prosthesis
US20220133864A1 (en) 2020-11-04 2022-05-05 Selecta Biosciences, Inc. Methods and compositions for reducing immune responses against immunoglobulin proteases
EP4274571A1 (en) 2021-01-05 2023-11-15 Selecta Biosciences, Inc. Viral vector dosing protocols
US20220323607A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CN114748689B (en) * 2022-04-14 2023-09-15 华南理工大学 Mammary gland reconstruction implant prosthesis hydrogel material and preparation method and application thereof
WO2024036324A1 (en) 2022-08-11 2024-02-15 Selecta Biosciences, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003785A1 (en) * 1986-11-20 1988-06-02 Vacanti Joseph P Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US4846835A (en) * 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
WO1992007525A1 (en) * 1990-10-31 1992-05-14 Baxter International Inc. Close vascularization implant material
WO1993007913A1 (en) * 1991-10-24 1993-04-29 Children's Medical Center Corporation Neomorphogenesis of urological structures in vivo from cell culture
WO1993008850A1 (en) * 1991-10-30 1993-05-13 Massachusetts Institute Of Technology Prevascularized polymeric implants for organ transplantation
WO1994025079A1 (en) * 1993-04-23 1994-11-10 Massachusetts Institute Of Technology Porous biodegradable polymeric materials for cell transplantation

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1995970A (en) * 1931-04-04 1935-03-26 Du Pont Polymeric lactide resin
US2609347A (en) * 1948-05-27 1952-09-02 Wilson Christopher Lumley Method of making expanded polyvinyl alcohol-formaldehyde reaction product and product resulting therefrom
US2664366A (en) * 1949-09-19 1953-12-29 Wilson Christopher Lumley Plasticized sponge material and method of making same
US2659935A (en) * 1950-03-18 1953-11-24 Christopher L Wilson Method of making compressed sponges
US2653917A (en) * 1950-06-15 1953-09-29 Christopher L Wilson Method of making an expanded material and the product resulting therefrom
US2676945A (en) * 1950-10-18 1954-04-27 Du Pont Condensation polymers of hydroxyacetic acid
US2683136A (en) * 1950-10-25 1954-07-06 Du Pont Copolymers of hydroxyacetic acid with other alcohol acids
US2703316A (en) * 1951-06-05 1955-03-01 Du Pont Polymers of high melting lactide
US2846407A (en) * 1954-01-13 1958-08-05 Wilson Christopher Lumley Method of making a detergent and solvent resistant sponge material
DE1228416B (en) * 1957-03-04 1966-11-10 Boehringer Sohn Ingelheim Process for the production of polyesters
US3531561A (en) * 1965-04-20 1970-09-29 Ethicon Inc Suture preparation
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3935065A (en) * 1971-09-02 1976-01-27 Roland Karl Doerig Procedure for conservation of living organs and apparatus for the execution of this procedure
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US4026304A (en) * 1972-04-12 1977-05-31 Hydro Med Sciences Inc. Bone generating method and device
US3883393A (en) * 1972-05-18 1975-05-13 Us Health Education & Welfare Cell culture on semi-permeable tubular membranes
US3826241A (en) * 1972-10-16 1974-07-30 Investors In Ventures Inc Implanting method
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US3974526A (en) * 1973-07-06 1976-08-17 Dardik Irving I Vascular prostheses and process for producing the same
US3992725A (en) * 1973-11-16 1976-11-23 Homsy Charles A Implantable material and appliances and method of stabilizing body implants
US3902497A (en) * 1974-03-25 1975-09-02 American Cyanamid Co Body absorbable sponge and method of making
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US3995444A (en) * 1974-11-08 1976-12-07 American Hospital Supply Corporation Organ perfusion system
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US4144126A (en) * 1975-05-21 1979-03-13 Beecham Group Limited Cell culture method
US4280954A (en) * 1975-07-15 1981-07-28 Massachusetts Institute Of Technology Crosslinked collagen-mucopolysaccharide composite materials
US4060081A (en) * 1975-07-15 1977-11-29 Massachusetts Institute Of Technology Multilayer membrane useful as synthetic skin
US4186448A (en) * 1976-04-16 1980-02-05 Brekke John H Device and method for treating and healing a newly created bone void
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4141087A (en) * 1977-01-19 1979-02-27 Ethicon, Inc. Isomorphic copolyoxalates and sutures thereof
US4328204A (en) * 1977-03-02 1982-05-04 Ethicon, Inc. Absorbable polymer-drug compounds and method for making same
US4243775A (en) * 1978-11-13 1981-01-06 American Cyanamid Company Synthetic polyester surgical articles
US4205399A (en) * 1977-06-13 1980-06-03 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
DE2853614A1 (en) 1978-01-25 1979-07-26 Bentley Lab IMPLANT
US4277582A (en) * 1978-03-03 1981-07-07 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4228243A (en) * 1978-07-13 1980-10-14 Toray Industries, Inc. Cell culture propagation apparatus
US4239664A (en) * 1978-10-31 1980-12-16 Research Corporation Anti-thrombogenic PVP-heparin polymer
US4456687A (en) * 1978-11-16 1984-06-26 President And Fellows Of Harvard College Agents for promoting growth of epithelial cells
US4713070A (en) * 1978-11-30 1987-12-15 Sumitom Electric Industries, Ltd. Porous structure of polytetrafluoroethylene and process for production thereof
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4501815A (en) * 1979-10-29 1985-02-26 Albert Einstein College Of Medicine Of Yeshiva University Article for culturing differentiated cells
US4304866A (en) * 1979-11-14 1981-12-08 Massachusetts Institute Of Technology Transplantable sheets of living keratinous tissue
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
DE3070993D1 (en) * 1979-12-20 1985-09-19 Dennis Chapman Polymerisable phospholipids and polymers thereof, methods for their preparation, methods for their use in coating substrates and forming liposomes and the resulting coated substrates and liposome compositions
US4356261A (en) * 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
US4347847A (en) * 1980-06-06 1982-09-07 Usher Francis C Method of hernia repair
CS216992B1 (en) * 1980-07-21 1982-12-31 Miroslav Stol Composite polymere material for the biological and medicinal utilitation and method of preparation thereof
US4576608A (en) * 1980-11-06 1986-03-18 Homsy Charles A Porous body-implantable polytetrafluoroethylene
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4416986A (en) * 1981-01-16 1983-11-22 Merck & Co., Inc. Methods of producing HBsAg
US4553272A (en) * 1981-02-26 1985-11-19 University Of Pittsburgh Regeneration of living tissues by growth of isolated cells in porous implant and product thereof
US4431428A (en) * 1981-09-30 1984-02-14 Trimedyne, Inc. Bio-artificial organ using microencapsulated enzymes
US4438198A (en) * 1981-09-30 1984-03-20 Trimedyne, Inc. Biochemically active matrix for use in a bio-artificial organ
US4446234A (en) * 1981-10-23 1984-05-01 The United States Of America As Represented By The Department Of Health And Human Services Vitro cellular interaction with amnion membrane substrate
US4458678A (en) * 1981-10-26 1984-07-10 Massachusetts Institute Of Technology Cell-seeding procedures involving fibrous lattices
US4505266A (en) * 1981-10-26 1985-03-19 Massachusetts Institute Of Technology Method of using a fibrous lattice
US4485096A (en) * 1982-02-26 1984-11-27 Massachusetts Institute Of Technology Tissue-equivalent and method for preparation thereof
US4439152A (en) * 1982-03-04 1984-03-27 Small Irwin A Method of jawbone abutment implant for dental prostheses and implant device
GR77865B (en) * 1982-03-25 1984-09-25 Coats Ltd J & P
US4520821A (en) * 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
US4528265A (en) * 1982-05-11 1985-07-09 Becker Robert O Processes and products involving cell modification
US4485097A (en) * 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
CA1200507A (en) * 1982-06-04 1986-02-11 Nobuo Sakao Method of preserving organ and apparatus for preserving the same
US4495174A (en) * 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
US4440921A (en) * 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
US4544516A (en) * 1982-07-28 1985-10-01 Battelle Development Corporation Collagen orientation
JPS5928472A (en) * 1982-08-09 1984-02-15 Koken:Kk Substrate for cell culture, cultivation and separation of cell using it
US4645669A (en) * 1982-10-04 1987-02-24 Albert Einstein College Of Medicine Of Yeshiva University Culturing and emplacement of differentiated cells in vivo
US4559298A (en) * 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US4446229A (en) * 1982-12-30 1984-05-01 Indech Robert B Method of tissue growth
US4757128A (en) * 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4689293A (en) * 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US5000963A (en) * 1983-06-14 1991-03-19 Hefton John M Method of treating the skin using human epidermal sheets
FR2559780B1 (en) 1984-02-21 1990-05-04 Tech Cuir Centre IMPLANTABLE BIOCOMPATIBLE COLLAGEN-BASED SYSTEMS FOR CELL STORAGE AND / OR CULTURE AND / OR CONTROLLED RELEASE OF ACTIVE INGREDIENTS
US4609551A (en) * 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4778749A (en) * 1984-06-01 1988-10-18 Karyon Technology, Inc. Tissue culture and production in permeable gels
US4675284A (en) * 1984-08-22 1987-06-23 Leevy Carroll M Process and apparatus for evaluating liver disease
US4757017A (en) * 1984-09-14 1988-07-12 Mcw Research Foundation, Inc. In vitro cell culture system
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4595713A (en) * 1985-01-22 1986-06-17 Hexcel Corporation Medical putty for tissue augmentation
US4868121A (en) * 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
DE3518150C1 (en) 1985-05-21 1986-10-23 Karl Prof. Dr.med. 7302 Ostfildern Theurer Process for the production of suspendible corpuscular particles of adhesive materials with molecular long-fibre crosslinking
US4627853A (en) * 1985-05-29 1986-12-09 American Hospital Supply Corporation Method of producing prostheses for replacement of articular cartilage and prostheses so produced
US4681763A (en) * 1985-06-11 1987-07-21 University Of Medicine And Dentistry Of New Jersey Composition for stimulating bone growth
US4853324A (en) * 1985-12-02 1989-08-01 Viles Joseph M Liver assist device employing transformed cell lines
DE3689650T2 (en) 1985-12-17 1994-05-26 United States Surgical Corp High molecular weight bioabsorbable polymers and implants thereof.
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4721096A (en) * 1986-04-18 1988-01-26 Marrow-Tech Incorporated Process for replicating bone marrow in vitro and using the same
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US4880622A (en) * 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
CH670759A5 (en) 1986-06-02 1989-07-14 Sulzer Ag
CH670760A5 (en) 1986-06-02 1989-07-14 Sulzer Ag
US4734373A (en) * 1986-06-24 1988-03-29 Bartal Arie H Apparatus for enhancing cell growth, preservation and transport
US5041138A (en) * 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
EP0282746A1 (en) 1987-02-19 1988-09-21 Takeda Chemical Industries, Ltd. Method for producing artificial cultured tissue
US4904259A (en) 1988-04-29 1990-02-27 Samuel Itay Compositions and methods for repair of cartilage and bone
JP2746387B2 (en) * 1988-09-22 1998-05-06 株式会社ビーエムジー Method for producing polyvinyl alcohol hydrogel
US4946938A (en) * 1989-08-01 1990-08-07 The University Of Pittsburgh A process for the catalytic synthesis of polyphosphazenes
US5326357A (en) * 1992-03-18 1994-07-05 Mount Sinai Hospital Corporation Reconstituted cartridge tissue

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003785A1 (en) * 1986-11-20 1988-06-02 Vacanti Joseph P Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US4846835A (en) * 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
WO1992007525A1 (en) * 1990-10-31 1992-05-14 Baxter International Inc. Close vascularization implant material
WO1993007913A1 (en) * 1991-10-24 1993-04-29 Children's Medical Center Corporation Neomorphogenesis of urological structures in vivo from cell culture
WO1993008850A1 (en) * 1991-10-30 1993-05-13 Massachusetts Institute Of Technology Prevascularized polymeric implants for organ transplantation
WO1994025079A1 (en) * 1993-04-23 1994-11-10 Massachusetts Institute Of Technology Porous biodegradable polymeric materials for cell transplantation

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022677A3 (en) * 1997-10-31 1999-07-08 Childrens Medical Center Penile reconstruction
AU751082B2 (en) * 1997-10-31 2002-08-08 Children's Medical Center Corporation Penile reconstruction
US6547719B1 (en) * 1997-10-31 2003-04-15 Children's Medical Center Corporation Penile reconstruction
US7572221B2 (en) 1997-10-31 2009-08-11 Children's Medical Center Corporation Reconstructing non-cartilage structural defects
WO1999025396A2 (en) * 1997-11-17 1999-05-27 The Regents Of The University Of Michigan Hybrid tissues for tissue engineering
WO1999025396A3 (en) * 1997-11-17 1999-07-29 Univ Michigan Hybrid tissues for tissue engineering
US6582960B1 (en) 1998-09-18 2003-06-24 Massachusetts Institute Of Technology Use of fibroblast growth factor 2 for expansion of chondrocytes and tissue engineering
WO2000033771A2 (en) * 1998-12-11 2000-06-15 Johnson Gerald W Implants filled with solid or semi-solid material
WO2000033771A3 (en) * 1998-12-11 2000-11-16 Gerald W Johnson Implants filled with solid or semi-solid material
WO2000044882A2 (en) * 1999-01-29 2000-08-03 Zen-Bio, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
WO2000044882A3 (en) * 1999-01-29 2001-08-09 Zen Bio Inc Methods and compositions for the differentiation of human preadipocytes into adipocytes
EP1335735A4 (en) * 2000-08-21 2007-05-16 Bernard O Brien Inst Of Micros Vascularised tissue graft
US7998735B2 (en) 2000-08-21 2011-08-16 Victorian Tissue Engineering Centre Pty. Ltd. Vascularized tissue graft
EP1335735A1 (en) * 2000-08-21 2003-08-20 Bernard O'Brien Institute of Microsurgery Vascularised tissue graft
WO2005021737A1 (en) 2003-09-01 2005-03-10 Aivogen Ag Follicular fluid for prolonged growth and survival of cells for cell therapies
US9314420B2 (en) 2005-10-26 2016-04-19 Jan-Eric Ahlfors Acellular bioabsorbable tissue regeneration matrices
EP2350274A4 (en) * 2008-10-21 2014-01-08 Gen Hospital Corp Cell transplantation
EP2350274A2 (en) * 2008-10-21 2011-08-03 The General Hospital Corporation Cell transplantation
US9730963B2 (en) 2008-10-21 2017-08-15 The General Hospital Corporation Cell transplantation
US10184110B2 (en) 2010-08-06 2019-01-22 The General Hospital Corporation System and apparatus for cell treatment
US10022486B2 (en) 2011-06-24 2018-07-17 Gearbox, Llc Device, system, and method including micro-patterned cell treatment array
US10610635B2 (en) 2011-06-24 2020-04-07 Gearbox Llc Device, system, and method including micro-patterned cell treatment array
EP3060060A4 (en) * 2013-10-25 2017-08-23 Collins, Scott Forrest Tissue engineered devices and methods for making same
US10159765B2 (en) 2013-10-25 2018-12-25 The Board Of Regents Of The University Of Texas System Tissue engineered devices and methods for making same
GB2526542A (en) * 2014-05-26 2015-12-02 David Anthony Waghorn Stem cell implanter and absorbable stem cell implant
US10799336B2 (en) 2014-09-09 2020-10-13 Klinikum Rechts Der Isar Der Technischen Universität München Medical/surgical implant
WO2019081708A1 (en) 2017-10-26 2019-05-02 Carl Freudenberg Kg Biocompatible soft tissue implant

Also Published As

Publication number Publication date
EP0797460A1 (en) 1997-10-01
US5716404A (en) 1998-02-10
AU717861B2 (en) 2000-04-06
CA2207757A1 (en) 1996-06-20
DE69534083T2 (en) 2006-03-30
EP0797460B1 (en) 2005-03-16
MX9704454A (en) 1998-02-28
DE69534083D1 (en) 2005-04-21
CA2207757C (en) 2005-04-05
JPH10510736A (en) 1998-10-20
AU4521796A (en) 1996-07-03
ATE290892T1 (en) 2005-04-15

Similar Documents

Publication Publication Date Title
US5716404A (en) Breast tissue engineering
MXPA97004454A (en) Tissue engineering
US5041138A (en) Neomorphogenesis of cartilage in vivo from cell culture
US6911202B2 (en) Cosmetic repair using cartilage producing cells and medical implants coated therewith
TWI258372B (en) Use of a device in manufacture of a medical product, a method of producing a device for repairing diseased or damaged tissue in a subject, and a device having tissue-like characteristics
US5830507A (en) Biotherapeutic cell-coated microspheres
AU2002306835B8 (en) Composition and methods for the production of biological tissues and tissue constructs
US5736372A (en) Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US6991652B2 (en) Tissue engineering composite
US20010016772A1 (en) Tissue implant
EP1496824A2 (en) Tissue composites and uses thereof
WO1999052356A1 (en) Creation of three-dimensional tissues
US20050002982A1 (en) Hybrid tissues for tissue engineering
JP4923235B2 (en) Bone-cartilage tissue regeneration implant
WO2001003750A1 (en) Human naturally secreted extracellular matrix-coated device
Lee et al. Breast reconstruction
KR20210042827A (en) A Novel Porous Scaffold and Methods for Preparing the Same
Thomas et al. Tissue Engineering Systems
Patel Development and characterization of a poly (ethylene glycol) hydrogel scaffold system for adipose tissue engineering
AU668959C (en) Biotherapeutic cell-coated microspheres
Burg Tissue engineering composite
Ong Assessment of collagen based polymer scaffolds for tissue engineering
Burg Tissue engineering composite
Peretti et al. Material Selection for Engineering Cartilage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2207757

Country of ref document: CA

Ref country code: CA

Ref document number: 2207757

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/004454

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1995943847

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995943847

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995943847

Country of ref document: EP